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ABSTRACT 
 
Systemic lupus erythematosus (SLE) is an autoimmune disease with variable and diverse 
clinical manifestations. Its etiology is unclear, but based on epidemiological and animal 
studies both genetic and environmental factors are involved. Several candidate susceptibility 
loci have been identified in case-control association studies and in linkage studies (Kelly et al. 
2002). Recent genome wide scans in different ethnic groups have suggested a number of 
susceptibility loci for SLE, but no gene has been identified as yet (Moser et al. 1998; Gaffney 
et al. 1998 and 2000; Shai et al.1999; Gray-McGuire et al. 2000; Lindqvist et al. 2000). These 
studies clearly indicate that multiple genes are involved in conferring susceptibility to SLE. 
 
In this nationwide study, we first ascertained a large group of patients and their relatives for a 
genetic study, characterized their phenotypes, conducted a genome-wide scan for SLE 
susceptibility loci with Finnish multiplex families, and followed the linkage study with a 
genetic association study in the selected region. The clinical characteristics were evaluated for 
all identified families, 53 of which were multiply affected by SLE. There were no differences 
in clinical and laboratory findings between sporadic and familial cases, suggesting that 
familial and sporadic SLE are the same entity. As an attempt to stratify the families according 
to a restricted subphenotype, we investigated the presence of antiphospholipid antibodies 
(aPLs). However, this subphenotype did not cluster in any families, thus providing no tools to 
subdivide the pedigrees into more homogeneous subsets.  
 
The genome-wide scan was performed on 35 multiplex families. We detected suggestive 
linkage in regions of chromosomes 6q and 14q, as well as to the HLA region on chromosome 
6p. The 14q locus and a partially overlapping region on chromosome 6q have been implicated 
previously. To obtain additional evidence for susceptibility loci on 6q and 14q, and in order to 
refine their positions, we added 31 more families from a sub-isolate in central eastern Finland 
(Savo region), in which founder effects have been noted previously (Nyström-Lahti et al. 
1994; Höglund et al. 1995). We performed fine-mapping, at 1 cM density, across the 
suggestive regions for linkage, and found evidence of excess sharing of a haplotype on 
chromosome 14q and excess transmission of a haplotype on chromosome 6q. These results 
confirmed the evidence for SLE susceptibility loci on chromosome 14q and 6q. Moreover, our 
results are compatible with the concept of a founder effect for susceptibility genes in SLE in 
central eastern Finland, and suggest a path to the identification of the putative susceptibility 
genes.   
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INTRODUCTION 
 
Systemic lupus erythematosus (SLE) is a rare autoimmune disease with female predominance. 
The prevalence of SLE in Finland is estimated as 28/100 000 (Helve 1985). Diagnosis of the 
disease is based on 11 American College of Rheumatology (ACR) classification criteria (Tan 
et al. 1982), of which four are sufficient. The clinical manifestations vary greatly from one 
person to another, and the course of the disease is characterized by periods of relapse and 
remission. The pathogenesis behind the disease remains unclear. The main immunological 
feature is uncontrolled formation of autoantibodies, leading to excess formation of immune 
complexes which deposit in tissues, causing inflammation and tissue damage. 
 
Based on epidemiological studies, there is clear clustering of SLE patients in families and the 
risk for siblings or second degree relatives of an affected individual to develop the disease is 
markedly increased, both supporting the role of genetic components to SLE susceptibility 
(Hochberg 1987; Vyse and Todd 1996; Sestak et al. 1999). Moreover, the concordance rate of 
SLE in MZ (~ 25%) is over ten-fold compared to that in DZ (~ 2%) (Deapen et al.1992; 
Grennan et al.1997). This supports not only a genetic contribution in the development of SLE, 
but also indicates that multiple genes are involved in disease expression (Wanstrat and 
Wakeland 2001). The mode of inheritance of SLE is however unknown. The disease is 
tiggered by environmental factors, such as viruses, certain drugs and sun exposure (Wanstrat 
and Wakeland 2001). 
   
Several candidate susceptibility loci for SLE have been identified in case-control association 
studies in man (including the HLA-region, Fc? receptors, and complement components), and 
in linkage studies with mouse models (reviewed by Kelly et al. 2002). To date, six genome- 
wide scans (Moser et al. 1998; Gaffney et al. 1998 and 2000; Shai et al.1999; Gray-McGuire 
et al. 2000; Lindqvist et al. 2000), using SLE as a phenotype, have been conducted in 
different ethnic groups. Each revealed several suggestive loci, but only six surpassed the 
significance threshold of LOD > 3.3. Recently, linkage to chromosome 2q37 (LOD 4.24) 
(Lindqvist et al. 2000), resulted in identification of a new susceptibility gene, programmed 
cell death 1 gene (PDCD1) (Prokurina et al. 2002). 
 
Due to the heterogeneous nature of SLE, recent genome wide scans have focused on specific 
subphenotypes in order to achieve more homogeneous sets of families, and to increase the 
statistical power to detect susceptibility genes (Nath et al. 2001 and 2002; Kelly et al. 2002; 
Namjou et al. 2002a and 2002b; Quintero-Del-Rio et al. 2002; Scofield et al. 2003). In total, 
17 regions have been significantly linked to SLE using both model-based and nonparametric 
approaches, 11 of them from such stratified studies. In addition, several other regions with 
suggestive linkage have been identified, but only some of those loci have been implicated in 
more than one study (Gaffney et al. 2000; Wakeland et al. 2001). These data, in addition to 
the twin studies, suggest that multiple genes are involved in conferring susceptibility to SLE. 
 
The aim of this study was to asscertain a well-characterized group of SLE patients as the basis 
for genetic studies, i.e. to conduct a genome-wide scan for SLE susceptibility loci in Finnish 
multiplex families, and further, to fine-map those genomic regions identified in the genome- 
wide scan as possibly linked to SLE. For this purpose, we evaluated SLE patients from 
hospital registrations all over Finland, which resulted in identification of more than 80% of all 
Finnish SLE patients requiring hospital-based treatment. Of the 252 identified families, 53 
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were multiply affected by SLE. The clinical characteristics of all families were evaluated. We 
also studied the prevalence of different aPLs, associated with thrombotic events, as one of the 
subphenotypes (antiphospolipid syndrome) of SLE, in sporadic and familial patients. The aim 
of these clinical studies was to evaluate the phenotype differences between sporadic and 
familial SLE as a possible tool for further genetic studies.  
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REVIEW OF THE LITERATURE 
 
1. Systemic lupus erythematosus 
 
1.1. General 
 
The term lupus (wolf) was already in use in the 13th century for the description of morbid 
cutaneous conditions, referring to erythematous (red) ulcerations about the face - a disease 
that eats away, bites, and destroys (Talbott 1993). Later, it was discovered that lupus 
erythematosus presents itself in two distinct forms: discoid lupus erythematosus, in which the 
manifestations are restricted only to skin, and systemic lupus erythematosus (SLE), in which 
many other organs are also affected. SLE, highly variable in its manifestations, is a potentially 
serious autoimmune disease of unknown cause. SLE is regarded as the prototype of 
autoimmune diseases, because of the wide variety of clinical and immunological 
manifestations. Approximately 90% of patients with SLE are women, and half of these are 
less than 30 of age when diagnosed (Cervera et al. 1993). 
The prevalence and incidence rates of SLE vary considerably between different populations. 
The overall prevalence in the United States and Hawaii ranges between 14.6 to 122 per100 
000 inhabitants (Rus et al. 2001). The prevalence of SLE in the United States is three to four 
times higher among African-Americans than among European-Americans, and manifests at a 
younger age and is more severe in this group (Fessel 1974; Kaslow and Masi 1978, Lawrence 
et al. 1998). The prevalence among African-Caribbeans and Asians is also much higher 
compared to Europeans (Rus et al. 2001).  
In predominantly European populations, outside of the United States, the prevalence estimates 
range from as low as 12.5 /100 000 females in England (Hochberg 1987) to as high as 
254/100 000 (both sexes combined) in Northern Ireland (Gourley et al. 1997). In Scandinavia, 
the prevalence of SLE ranges from 21.7/100 000 in Denmark to 35/100 000 in Iceland and 
40/100 000 in Sweden (Voss et al. 1999; Gudmundsson and Steinsson 1990). In Finland the 
prevalence of SLE is estimated to be 28/100 000 (Helve 1985). 
The average annual incidence of SLE in the United States is 1.8 to 7.6 cases per 100 000 
persons per year (Rus et al. 2001). In Sweden, Iceland, and the United Kindom reported 
overall incidence rates for SLE are 4.8, 3.3 and 3.7 to 3.8 per 100 000 persons per year, 
respectively (Rus et al. 2001). 
The diagnosis of SLE is based on both clinical symptoms and laboratory findings. As an aid 
for diagnosis, the American College of Rheumatology published SLE classification criteria 
(Tan et al. 1982), as presented in Table 1. While these were later updated (Hochberg 1997), 
we used the 1982 criteria. A diagnosis of SLE is made if the patient meets at least four of 11 
criteria. Low serum complement level supports the diagnosis. A diagnosis of SLE is unlikely 
in the absence of antinuclear antibodies (ANA), as these are detected sporadically in up to 2% 
of the female population over the age of 40 (Wakeland et al. 2001). 
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Table 1. The 1982 systemic lupus erythematosus classification criteria from the American 
               College of Rheumatology (Tan et al. 1982). * 
 
Category   Symptom 
Skin criteria                1.   Malar (butterfly) rash (over the cheeks and nose) 
   2.   Discoid rash (scarring rash in sun-exposed areas) 
   3.   Photosensitivity 
   4.   Oral ulcerations 
Systemic criteria 5.   Arthritis (non-erosive) 
   6.   Serositis (pleurisy or pericarditis) 
   7.   Renal disorders (proteinuria or cellular casts) 
   8.   Neurological disorders (seizure or psychosis with no other 
         etiology 
Laboratory criteria      9.   Hematologic: 
 hemolytic anemia or leukocytopenia or lymphocytopenia  or 
thrombocytopenia 
                                   10.  Immunologic: 
  Positive LE cell preparation or anti-dsDNA antibodies or anti-
Sm-antibodies or false positive serologic test for syphilis 
                                    11. ANA (antinuclear antibody) 
     
*Any four of these 11 criteria, present serially or simultaneously during any interval of 
observation, establish the diagnosis of SLE. Table adapted from Wakeland et al. (2001). 
 
1.2. Etiology 
 
1.2.1. Hormonal and environmental factors 
 
The strongest risk factor for developing SLE is being female. The hormonal hypothesis for the 
development of the disease is supported by the lower female to male sex ratio in early onset 
(age 0-9; ratio 2:0) and late onset (age 60+, ratio 2.3) SLE, compared to 8:1 among females 
and males in young adulthood (20-39 years) (Hochberg 1993). Studies of sex hormones in 
patients with SLE have implicated hormonal aberrations, including high estrogen levels, low 
androgens, and abnormalities in the prolactin-gonadal axis (Walker and Jacobson 2000; 
McMurray 2001; McMurray and May 2003). These findings are supported by mouse models 
of lupus (Roubinian et al. 1977). Moreover, hormones, especially those used as estrogen 
replacement therapy, have been suggested as etiological factors for SLE (Sanchez-Guerrero et 
al.1995 and 1997; Meier 1998). Both the past use of oral contraceptive pills (Sanches-
Guerrero et al. 1995) and hormone replacement therapy (HRT), especially when used for 
longer periods, are associated with a slightly increased risk of developing SLE (Sanches-
Guerrero et al. 1997; Meier et al. 1998). 
There is preliminary evidence that a defective hypothalamo-pituitary-adrenal (HPA) axis is 
present in both mouse and human lupus (Gutierrez et al. 1998; Lecner et al. 2000). The HPA 
axis is the chief component of the stress response. In stress situations, increased concentration 
of serum glucocorticoids are essential for the prevention of autoreactive or unrestrained 
amplification of the immune response, which may result in self-injury and autoimmunity 
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(Mok and Lau 2003). In SLE, the dysregulated HPA axis may be responsible for disease 
susceptibility and progression. 
Allthough genetic factors and the hormonal milieu may create a predisposition to SLE, 
initiation of the disease probably results from several environmental triggers. The Epstein 
Barr virus infection is clearly associated with SLE in young adults and children (James 1997). 
Ultraviolet radiation often exacerbates the manifestations of established SLE, but can also 
trigger the disease, especially when a person is exposed to sun after viral or bacterial infection 
(Gilliam and Sontheimer 1982). Aromatic amines and hydrazines and their derivates can 
induce SLE-like disease, and exist in a variety of compounds used in agriculture, industry, 
and commercial applications, as well as in drugs (Mok and Lau, 2003). Such drugs include 
hydralazine and procainamide, the best-characterized drugs for the development of SLE in 
humans (so called drug induced lupus) (Pramatarov 1998). Finally, some dietary factors and 
smoking are also associated with the development of SLE (Prete 1985; Harbige 1996; 
Chaussy et al. 2003; Formica et al. 2003). 
   
1.2.2. Genetic factors 
 
The genetic predisposition for SLE was first suggested by the familial occurrence of the 
disease and by analyses of concordance rates in monozygotic twins. The concordance rate for 
MZ (~25%) relative to DZ (~ 2%) is over ten fold, supporting not only the genetic 
contribution in the development of the disease but also indicating that multiple genes are 
involved in disease expression (Deapen et al. 1992; Grennan et al. 1997). Based on family 
studies, approximately 10 to 12 % of SLE patients have a 1st or 2nd degree relative with the 
disease (Hochberg 1987; Lawrence et al. 1987). Moreover, the calculation of ?s, the ratio of 
the risk of disease among the siblings of affected individuals compared to disease prevalence 
in the general population, also supports a potential role for genetic predisposition in disease 
susceptibility (Risch 1987). If ?s is close to 1.0, there is no evidence for familial clustering 
(Vyse and Todd 1996). In SLE, the estimated ?s is 20, which means that a sibling of an 
affected individual has a 20 times greater risk of developing SLE than a member of the 
general population (Vyse and Todd 1996). As a comparison, the ?s for a monogenic 
Mendelian disease, such as cystic fibrosis, is over 10 times higher (?s = 500). The higher the 
?s, the easier it is to map susceptibility genes (Lindqvist and Alarcón-Riquelme 1999). 
 
Case-control association studies in humans have implicated a number of susceptibility loci, 
including the HLA region, Fc? receptors, and complement components, as evidence for a 
genetic contribution in the development of SLE (Kelly et al. 2002). In addition, SLE studies 
using inbred mouse strains suggest multiple susceptibility loci (Kelly et al. 2002). 
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2. Pathogenesis 
The exact pathogenesis of SLE remains elusive. A complicated and multifactorial interaction 
of various genetic, environmental, hormonal, and immunoregulatory factors are probably 
involved (Mok and Lau 2003). Immunologically, SLE is characterized by loss of self-
tolerance leading to T- and B-cell hyperactivity, cytokine dysregulation, and uncontrolled 
production of autoimmune antibodies. Secreted autoantibodies can be deposited in tissues, 
causing inflammation and tissue damage (Hahn 1993). They may also form circulating 
immune complexes (ICs) with various antigens, which are released in excess due to abnormal 
apoptosis of various cell types (Robson and Walport 2001; Tsokos 2001). Moreover, defects 
in the clearance system of apoptotic cells and ICs favour the deposition of ICs in tissues 
causing inflammation (Hahn 1993; Robson and Wahlport 2001).  
Autoantibodies are directed to intracellular (e.g. dsDNA, histones), cell-surface (red cells, 
white cells, platelets) and extracellular constituents (Emlen 1993; Malide et al. 1993; Stockl et 
al. 1994). The hallmark of SLE is elevated serum level of immunoglobulin G (IgG) antibodies 
to nuclear constituents (so called antinuclear antibodies, ANA). 
The decreased clearance of ICs is caused by a deficiency of complement components and/or 
defects in the receptors for the complement (CRs) and Fc portion of immunoglobulin (Fc?R). 
Complement is required for fixing ICs to erythrocytes (solubilization), which are then 
together transported from the circulation to mononuclear phagocyte system (MPS) in liver or 
spleen. Without solubilization, the ICs are deposited in tissues (Emlen 1993; Salmon 1993). 
In order to bind the ICs to complements and further to erythrocytes, Fc?Rs and CRs are 
needed. They are also needed in MPS, where erythrocyte-fixed immune complexes are bound 
to fixed-tissue phagocytes, stripped from the erythrocytes, phagocytozed and degraded 
(Emlen 1993; Salmon 1993). 
Immune complexes can also be formed in situ, as antibodies bind directly to tissue antigens. 
Complement activation is not required for the degradation of in situ ICs, and these are cleared 
from tissue primarily by Fc?Rs on fixed tissue magrophages, with binding of the Fc portion in 
IgG containing ICs (Emlen 1993).  
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    Fig. 1   The hypothetical scheme for pathogenesis of systemic lupus erythematosus, 
                adapted from Mok and Lau (2003). 
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3. Clinical characteristics  
 
The clinical manifestations of SLE are extremely variable among patients, and the course of 
the disease is characterized by periods of remission and relapse. Almost any organ can be 
involved, including joints, skin, kidneys, heart, lungs and brain (Gripenberg-Gahmberg and 
Konttinen 2002). A typical patient is a young woman in her child-bearing years, presenting 
with intermittent fatigue, joint pain and swelling, rashes (butterfly rash), low white blood cell 
count, anaemia, and chest pain due to pleuritis. Around 40% of patients develop nephritis 
(Cervera et al. 1993). Vasculitis (an inflammation of blood vessels) and serositis (pleurisy 
and/or pericarditis) are present in 20 to 40% of patients, and neuropsychiatric manifestations, 
most frequently seen as headaches and depression, in 25 to 80% (Gripenberg-Gahmberg and 
Konttinen 2001). Moreover, coronary artery disease and myocardial infarction are frequently 
seen, and in fact, nowadays are the leading causes of death of SLE patients (Urowitz et al. 
1976; Abu-Shakra and Lee 1995; Manzi et al. 1997). Around 30% of patients have 
antiphopholipin antibodies (aPL) (Love and Santori 1990; Cervera et al. 1993), predisposing 
these patients to thrombosis, recurrent fetal loss and/or thrombocytopenia, a syndrome called 
antiphospholipid syndrome (APS). 
A severe renal failure can be the first symptom of the disease. End-stage renal disease 
(ESRD) requiring hemodialysis or renal transplantation, develops in 5 to 22% of patients with 
lupus nephritis (reviewed by Mojcik and Klippel 1996). The overall 10-year survival rate for 
SLE patients has been reported to be between 75 to 92%, with more than 90% of patients 
surviving longer than 5 years (Ruiz-Irastorza et al. 2001; Cervera and Asherson 2003). Lower 
survival rates are seen in patients with nephropathy. The outcome of renal transplantations in 
SLE patients is good, however, and the survival and nephritis recurrence rate does not differ 
from those of other patients with ESRD (Mojick and Klippel 1996).  
 
 
4. Antiphospholipid syndrome (APS) 
 
Antiphospholipid syndrome (APS) is defined as the association of aPLs with a variety of 
clinical phenomena, including arterial and venous thrombosis, thrombocytopenia, and 
obstetric complications in the form of recurrent miscarriages, fetal death, or fetal growth 
retardation (Hughes 1993, Branch 1994). APS is probably the most common hypercoagulable 
disorder (Thomas 2001). Thrombotic events occur in approximately 30% of patients with 
aPLs (Galli and Barbui 1999). APS can be present without any underlying disease (primary or 
idiopathic APS) (Asherson et al. 1989), or it can be related to systemic lupus erythematosus, 
to other autoimmune or neoplastic diseases, or other pathological conditions (secondary APS) 
(Alargon-Segovia et al. 1989). An international consensus of classification criteria for APS 
has been recently published (Wilson 2001). 
 
The aPLs are a large and heterogeneous family of immunoglobulins, directed against anionic 
phospholipids or specific plasma proteins with affinity to anionic (phospholipid) surfaces 
(Galli et al. 1998; Keswani and Chauhan 2002). The clinically most relevant and best-studied 
aPLs are lupus anticoaculant (LA) and anticardiolipin antibodies (aCL), both associated with 
arterial and venous thrombosis with variable specificities and sensitivities (Levine et al. 
2002). aCL antibodies are also detected in various non-thrombotic conditions, such as 
infections (HIV, Lyme disease, and syphilis), and associated with the use of certain drugs 
(Triplett et al. 1988). Moreover, these ”benign” antibodies are seen in some proportions in the 
general population, especially in older groups, probably as a response to common viral 
illnesses or with coexistent chronic diseases (Vila et al. 1994; Petri 2000).  
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In the 1990´s it was found that aCLs do not bind directly to phospholipids, but rather to 
plasma proteins, with affinity to anionic (phosphpolipid) surfaces. Of these plasma proteins, 
?2-glycoprotein (?2-GPI) and prothrombin are the most studied (Galli and Barbui 1999). 
Anti-?2-GPI antibodies are said to be more closely associated with thrombosis than is aCL. 
Moreover, “pathogenic” aCLs, associated with APS and thrombosis, are distinguished from 
“benign” aCLs, since they are ?2-GPI-dependent. In non-thrombotic contexts, aCLs are ?2-
GPI-independent (Galli et al. 1990; McNally et al.1995). Antiprothrombin antibodies have 
been associated with pregnancy loss in patients with APS (von Landenberg 2003), but 
whether they increase risk of thromboemolic events remains unknown.  
 
In addition to the thrombogenic nature of different aPLs, there is evidence that aPL antibodies 
to ox-LDL, anti- ?2-GPI, and anti-prothrombin antibodies would have a role in premature 
atherosclerosis in SLE and APS. Patients with both diseases have a high risk for 
atherosclerotic cardiovascular events (Witztum et al. 1991; Vaarala et al. 1993; Witztum and 
Horkko 1997; Jara et al. 2003).  
 
Familial clustering of raised antibody levels (Goldberg et al. 1995; Hellan et al. 1998), and 
HLA linkages suggests probably that the antibodies occur in genetically susceptible hosts in 
response to some antigenic challenge (Sebastiani et al. 1996; Wilson and Gharavi 1996; 
Granados 1997).  
 
Several hypotheses have been proposed to explain the pathogenesis of thrombosis in patients 
with APS (Levine et al. 2002). To date, there is no definitive association between specific 
clinical manifestations and particular subgroups of antiphospholipid antibodies. Therefore, 
multiple tests for these antibodies are recommended, since patients may be negative according 
to one test yet positive in another (Levine et al. 2002). 
 
 
5. Genetics of complex autoimmune diseases 
 
5.1. Penetrance and genetic heterogeneity 
 
The phenotype in complex traits is most likely caused by the interaction of environmental 
factors and multiple genes (MHC and non-MHC genes), which may be common in the 
general population and alone are insufficient or even necessary for disease expression. This 
means that each single gene as such has a small effect on the risk for the disease (low 
penetrance) (Lander 1996; Chakravarti 1999). Furthermore, even in the presence of a full set 
of susceptibility alleles at multiple loci, overt disease may not always develop (incomplete 
penetrance), and thus environmental factors may be needed to trigger the disease (Vyse and 
Kozin 1996). Complex diseases are traits that do not follow Mendelian law of inheritance, and 
the pathogenesis is often poorly understood, hence candidate genes are difficult to determine, 
especially when the functions of most genes remain poorly understood. 
 
Genetic heterogeneity refers to the presence of multiple combinations of genes within the 
genome that are capable of causing a similar or identical disease phenotype (Wanstrat and 
Wakeland 2001). For example, two or three different combinations of genes within one 
family, or in different populations, can result in identical disease phenotypes. This genetic 
heterogeneity is created by various forces during generations, including the chance effects of 
genetic drift and population bottlenecks, and also selection. 
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Genetic heterogeneity in complex diseases is apparent from association and linkage studies in 
human and mouse models (Kelly et al. 2002). Association studies for candidate susceptibility 
genes in both type I diabetes and in SLE, for example, have revealed significant variations 
between different ethnic groups in the association of specific alleles and disease phenotypes 
(Leech et al. 1995; Salmon et al. 1996). This ethnic diversity is also apparent in many linkage 
studies in humans, with associations of specific genomic intervals only in specific ethnic 
groups (Moser et al. 1998; Lindqvist et al. 2000). Genetic heterogeneity has also been 
observed in linkage studies in mice, where for example, lupus susceptibility was mediated in 
the lupus-prone BXSB strain by loci that were not involved in diseases susceptibility in the 
NZM2410, NZB/NZW or MRL/lpr mouse strains (Hogart et al. 1998).  
 
5.2. Epistatic interactions 
 
Epistastis is defined as the interaction between different genes, where the effect of one locus 
linked to the trait is altered or masked by effects at another locus (Cordell 2002). This means 
that the power to detect the first locus is likely to be reduced, and elucidation of the joint 
effects at the two loci is hindered by their interaction (Cordell 2002). In complex diseases like 
SLE or type I diabetes, where there are more than two loci involved, the situation is even 
more complicated due to possible interactions between some or all contributing loci (Cordell 
2002). 
 
Evidence for epistatic interactions among susceptibility alleles have been reported in both 
mouse models and human linkage studies for many complex autoimmune diseases (Prins et 
al. 1993; Gray Mc-Guire et al. 2000; Morel et al. 2000). Although the extent of epistasis in 
human is unknown, many functional polymorphisms influencing immune recognition and 
responsiveness are probably caused by epistatic interactions, and will therefore be a 
component of autoimmune disease susceptibility in most species (Wanstrat and Wakeland 
2001). 
 
 
6. Identifying disease susceptibility genes 
 
6.1. The role of phenotyping    
 
The basis for identification of susceptibility genes for any disease is to collect families having 
several affected individuals. Moreover, these families should be clinically well defined, and 
show intergenerational transmission of the disease. In complex diseases, however, the 
phenotype is often very broad, complicating the diagnosis. In SLE, identification of any four 
of 11 classification criteria in an individual is enough for diagnosis (Tan et al. 1982). 
However, these four criteria can overlap or be totally different in different individuals. 
Moreover, the onset of the disease and the severity of manifestations vary greatly from one 
patient to another; one person may have only mild pain in their joints, while another can 
suffer from severe kidney, central nervous system, or cardiac manifestations. Hence, there are 
not only variations between different phenotypes, but also variations within phenotypes, both 
reflecting the broad clinical diversity and the extent of genetic heterogeneity in SLE patients. 
Finally, the diagnosis may be biased due to the course of the disease; SLE is characterized by 
periods of remission and relapse and hence the disease can be missed, and patients with 
milder symptoms can be undiagnosed.  
Grouping patients and families according to clinical covariates has been a successful strategy 
for gene identification, at least in some complex diseases. Association with lower age at onset 
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has led to gene identification by classical positional cloning of the breast-ovarian cancer gene 
BRCA1 (Miki et al. 1994; Wooster and Stratton 1995). Similarly, stratification has been 
successful in studies with thyroid carcinoma and psoriasis, with convincing evidence of 
linkage to chromosome 2q22 and HLA regions, respectively (Samuelsson 1999; McKay et al. 
2001). Recent genetic studies employing a genome-wide scan approach for SLE have focused 
on stratification of patients with subphenotypes, with convincing linkage results (Nath et al. 
2001 and 2002; Kelly et al. 2002; Namjou et al. 2002a and 2002b; Quintero-Del-Rio et al. 
2002; Scofield et al. 2003). Stratification often requires either large pedigrees with multiple 
affected family members with the same subphenotypes or large numbers of nuclear families 
with the same phenotypes, however, both of which can be difficult to ascertain in small 
populations with rare complex diseases.  
 
6.2. The advantage of founder population 
 
Another way to decrease the risk of genetic heterogeneity is to choose a study population with 
a founder effect. This means that the increased frequency of some rare genetic disorders 
within a population can be assumed to have occurred through enrichments of a single 
ancestral disease-causing allele (de la Chapelle and Wright 1998; Kere 2001). The founder 
chromosome with the disease-causing gene is transferred over time through healthy carriers to 
apparently unrelated patients. Despite recombination, which tends to shorten the shared 
common chromosomal region in each meioisis throughout generations, the ancestral genetic 
constitution in the present-day patients is likely to have been preserved in close vicinity to the 
disease gene. When the disease-associated chromosomes are genotyped with microsatellite 
markers, certain alleles for each marker show remarkable overrepresentation when compared 
to the allele frequencies in the general population. Disease associated alleles are said to be in 
linkage disequilibrium, whereas random alleles are present at more distant loci, and thus have 
reached an equilibrium (Kere 2001; Jorde 1995). 
Examples of populations with founder effects include Finland, Sardinia, Iceland, and Japan 
(Wright et al. 1999). All of these countries are geographically isolated, population expansions 
have occurred by growth rather than immigration. In these countries, allelic heterogeneity 
may have been diminished by genetic drift before expansion (Wright et al. 1999). Founder 
populations have proven to be very useful for finding genes in monogenic diseases, which 
follow the Mendelian law of inheritance. For example, in Finland there are over 30 rare 
recessive diseases, for most of which the gene has been successfully mapped utilizing linkage 
disequilibrium in positional cloning (de la Chapelle and Wright 1998; Peltonen et al. 1999). 
These diseases, also termed the “Finnish disease heritage”, are typical to Finland and rarely 
seen in other countries, indicating an isolated gene pool for the Finns. 
Lessons from mapping monogenic disorders have encouraged researchers to use founder 
populations to study the genetically more complicated complex diseases. Indeed, the reduced 
genetic heterogeneity and the ability to utilize linkage disequilibrium in founder populations 
favor their use over more heterogeneous populations in mapping susceptibility genes for 
complex diseases. Moreover, Finland has a good administrative infrastructure, initially 
created during the regime of King Gustavus of Vasa in 1523-1560. At this time church 
records were created; these have been a major source of information for genetic studies today. 
The church records reported births and deaths, marriages, and movement of families, and 
hence today provide a highly reliable source of genealogical information, especially since 
>90% of the Finnish population still belongs to the Evangelic Lutheran State Church 
(Peltonen et al. 1999).  
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Encouraging results mapping genes for complex diseases in Finland include asthma, psoriasis, 
schizophrenia, multiple sclerosis, and familial combined hyperlipidemia (Laitinen et al. 2001; 
Asumalahti et al. 2002; Hovatta et al. 1999; Kuokkanen et al. 1997; Pajukanta et al. 1998).  
 
 
7. Mapping susceptibility genes 
 
7.1. Linkage analysis 
 
Linkage analysis is a practical way to approach the identification of disease susceptibility 
genes that are unknown or unsuspected, without prior knowledge of the function of those 
genes. With a genome-wide scan we can identify possible susceptibility loci, then narrow 
down the region with additional genetic markers (using association), and finally clone the 
gene. The markers used in linkage studies are short tandem repeats, “microsatellites”, those 
DNA sequences that show considerable variability among individuals (polymorphism) but 
that are selectively neutral. Recently, single nucleotide polymorphisms (SNPs), single base 
pair variations which account for approximately 90% of human DNA polymorphism, are 
increasingly used in studies of complex diseases (Collins et al. 1998). Investigating genetic 
linkage depends on having families. The main hypothesis is that alleles from two loci tend to 
segregate together in a family if they are located physically close to each other on a 
chromosome (Risch 2000). The easiest way to identify linkage is to use affected sibpairs, 
where allele sharing in excess of 50% (the expectation of no linkage) is sought (Risch 2000). 
However, linkage analyses using sibpairs are powerful only if there is a large number of 
sibpairs available (Kruglyak and Lander 1995).  
The extent of linkage is determined as a function of the distance between two loci, measured 
by the number of crossovers between the two loci among the observed meioses, i.e., 
recombination fraction (theta,) (Xu et al. 1998). The recombination fraction and the evidence 
for linkage can be estimated by a LOD score (logarithm of odds), which is a likelihood-based 
parametric linkage approach. The LOD score represents log10 of the ratio of the likelihood 
that two loci (marker and disease) are linked at a certain recombination fraction (?) compared 
to the likelihood that they are not (? = 0.5) (Ott and Bhat 1999; Terwilliger and Ott 1994).  
In parametric linkage analyses the mode of inheritance is known. It is widely used in 
Mendelian traits, where parameters such as penetrance and disease allele frequencies are 
usually estimated by epidemiological surveys (Ott and Bhat 1999). Linkage analyses can be 
performed either by two-point or multipoint linkage analyses (Xu et al.1998). Lander and 
Kruglyak (1995) introduced criteria for the significance of genome scans. In Mendelian traits 
LOD > 3.6 (p = 2 x 10-5) and LOD > 2.2 (p = 7 x 10-4) are regarded as thresholds for 
significant and suggestive linkage, respectively. The definition, however, is based on highly 
dense marker maps and complete information. 
In complex diseases where the mode of inheritance is unknown, the LOD score may still be 
calculated. Because the parameters in complex traits are difficult to define, both dominant and 
recessive inheritance models are used to calculate LOD scores with different gene frequencies 
and penetrance values to determine, which model gives the highest scores. Recommendations 
for LOD scores in complex diseases are LOD > 3.3 and LOD > 1.9 for significance and 
suggestive linkage, respectively (Lander and Kruglyak 1995), again with complete 
information and highly dense marker maps. Another way to measure linkage in complex 
diseases is to use non-parametric linkage (NPL) analysis. This is a model-free method, 
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requiring no knowledge of the inheritance pattern of the disease. This method considers 
alleles shared by affected individuals, and ignores those unaffected. For example, the program 
package GENEHUNTER (Kruglyak et al 1996) calculates NPL in extended pedigrees, 
assessing identity by-descent (IBD), allele sharing among affected relatives within pedigrees.  
7.2. Allelic association and linkage disequilibrium  
Allelic association is another nonparametric approach to map disease genes. In genetically 
complex traits association can be used for evaluation of candidate loci as well as for fine-
mapping of a region, once a region of interest has been identified (Lander and Schork 1994; 
Pericak-Vance, 1998). Allelic association can be due to either association or linkage. In 
association, the frequencies of marker alleles are significantly increased or decreased, and 
hence deviate from a random occurrence with respect to the disease phenotype. Allelic 
association can, however, occur by chance. This may be the case if the population is 
substructured, as occurrs in recent admixture of populations. Here alleles may show statistical 
association simply by chance, due to differences in allele frequencies in the two mixing 
populations (Lander and Schork 1994; Pericak-Vance 1998). 
Two types of association studies exist, case-control and family based studies. In case-control 
studies, allele frequencies are compared between unrelated affected individuals and a set of 
matched (sex, age, onset of disease) healthy controls. The advantage of case-control studies 
are that cases and controls are easy to obtain and genotype. Isolated populations with genetic 
homogeneity are suggested as good case-control sample sets (Peltonen et al. 2000). As 
mentioned above, however, population substructure has to be taken into account (Kere 2001). 
The advantage of family-based association studies is that this approach eliminates the concern 
that population substructure may be the cause of the association (Pericak-Vance 1998). 
Family-based studies compare frequencies of alleles transmitted from healthy parents to an 
affected child. The transmission disequilibrium test (TDT) is the most widely used test to 
measure association. It is also very powerful for detecting linkage in genetically complex 
traits, where the genetic effect is small (Spielman et al. 1993; Risch and Merikangas 1996).  
In linkage disequilibrium (LD), two marker alleles lie so close to the disease susceptibility 
allele that they are inherited together over many generations. Thus the same allele will be 
detected in affected individuals in multiple, apparently unrelated families. The physical extent 
of the chromosomal region preserved around the mutation is dependent on the number of 
generations (reflecting the number of meiotic recombinations) since the disease allele was 
transmitted from a common ancestor (de la Chapelle and Wright 1998). LD is conceptually 
based on the same phenomenon as linkage analyses but considers the accumulation of 
recombinations over many generations, so that the recombination distances measured are very 
small (< 1cM), and the recombination events can only be inferred based on the level of 
sharing of the same allele (Pericak-Vance 1998). 
LD genome-wide scans have been regarded as the method of choice for mapping complex 
diseases (Lander et Schork 1994; Kruglyak 1999; Reich et al. 2001).They have been very 
useful for mapping susceptibility genes within genetically young isolates (<200 generations) 
(Schaid 1998). Recently, however, it was discovered that LD is not restricted to within only 
one population but also exists extensively between populations. Association studies with 
dense single nucleotide polymorphic markers (SNPs) led to the discovery that the human 
genome is organized into haplotype blocks, regions which for some reason have avoided 
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historical recombination, and in which LD is extensive. These haplotype blocks show limited 
diversity. In fact, only a few common haplotypes account for over 80% of all haplotypes in 
the block (Daly et al. 2001; Patil et al. 2001; Gabriel et al. 2002).   
The length of the haplotype blocks vary somewhat between different populations. In African 
and African-American populations the mean size of a block is around 22 kb, compared to 44 
kb in European and Asian populations (Gabriel et al 2002). Over 50% of all haplotypes are 
shared by these four populations, and boundaries of the blocks are highly correlated across 
different populations, strongly supporting the common African origin of all human 
populations (Reich et al 2001; Gabriel et al.2002). 
The major advantage of these blocks is that over 80% of the haplotypes are defined by less 
than 10% of the SNPs in the block. Therefore, instead of genotyping all SNPs within the 
block, only a small fraction, defined as tagging SNPs, are needed to capture most of the 
haplotypes. Before this can be done, however, a haplotype map covering the whole genome 
must first be constructed. This probably involves genotyping millions of SNPs in order to find 
the tagging SNPs, but after this work is done, only a subset of SNPs are required for whole- 
genome LD mapping (Daly et al.2001; Patil et al. 2001; Gabriel et al. 2002; Reich et al. 
2002). 
 
7.3. Simulation 
 
Simulation is an appropriate method to estimate the power to detect linkage or LD between 
alleles at the disease and marker loci for a given population (Laitinen et al. 2001). One can 
generate genotypes with random artificial data, constructed with the same marker density, 
informativeness and exact pedigree structure as those of a real study. The data are simulated 
over N iterations, giving the threshold for suggestive linkage (NPL score exceeded once per 
genome scan at random) and significant linkage (NPL score exceeded once per 20 genome 
scans at random), as suggested by Lander & Kruglyak (1995). 
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8. SLE genetics    
 
8.1. Mouse genetics of SLE  
 
Genetic studies with mouse models have, over the years, revealed valuable information 
concerning the pathogenesis and genetics of many complex diseases, with results serving as a 
possible guide to reveal the syntenic regions in humans (i.e. chromosomal regions with 
homologous loci in human and mice) in the search for susceptibility genes. In SLE, the most 
useful animal model for the investigation of genetic contributions to disease have included 
those mouse strains, which develop lupus-like disease spontaneously. These include hybrids 
of New Zealand black (NZB) and white (NZW) mice (Drake et al. 1995), MRL mice, 
homozygous for lymphoproliferation (lpr) mutation (Cohen and Eisenberg 1991), and BXS 
mice, which carry a SLE disease-accelerating gene on the Y chromocome (Izui et al. 1995). 
These strains are primary models for severe lupus-like glomerulonephritis. The use of mice in 
genetic studies has many advantages. Directed breeding of backcross or F2 intercross mice 
allows the generation of large numbers of affected offspring, which can then be mapped for 
contributing genes. The phenotypes of different mice strains is much more uniform than that 
of humans, and environmental factors can be more carefully monitored (Vyse and Kotzin 
1996).  
 
To date, numbers of chromosomal regions containing genes for mouse lupus susceptibility 
have been identified (Table 2). There are several susceptibility loci, which are mapped to 
similar regions across multiple mouse strains, specifically on chromosomes 1, 4, 7, and the 
MHC region on chromosome 17. This suggests that at least some susceptibility genes may be 
shared between different lupus-prone mouse strains, yet the majority of the loci are strain 
specific. This indicates that each lupus-prone mouse strain is susceptible in part due to a 
unique set of disease genes, reflecting the genetic heterogeneity in susceptibility to mouse 
lupus.  
 
Despite the advantages mouse models can offer to studies of susceptibility genes in humans 
(e.g. large number of offspring, monitoring of environmental factors), it must be emphasized 
that one mouse model may be representative only for one patient, and that the same genetic 
mutations may not underlie both mouse and human diseases (Vyse and Kotzin 1996). 
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Table 2. Mouse susceptibility loci and their equivalent human syntenic regions (if known).     
Adapted from Kelly et al. 2002 
 
 
 Mouse 
chromosome 
Approxi-
mate 
placement 
(cM)a 
Identified 
mouse loci 
Mouse 
model 
Human 
syntenic 
regionb 
Reference 
1 7.7 
33 
71 
88 
90 
95 
100 
Bxs4/Sle10 
Bxs1/Sle7 
Bxs2/Sle8 
Sle1 
Lbw7 
Nba2 
Bxs3/Yaa4 
BXSB 
BXSB 
BXSB 
NZM 
NZB/NZW 
NZB/NZW 
BXSB  
8 
2q33-qter 
2q11-13 
1q22-2 
1q21-2 
1q21-2 
1q41-4 
Haywood et al. 2000 
Hogarth et al. 1998 
Hogarth et al. 1998 
Morel et al. 1994 
Kono et al.1994 
Vyse et al.1997 
Hogarth et al. 1998 
3 35 
40 
Sles3 
Bxs5/Sle11 
NZM 
BXSB 
3q25 Morel et al. 1999 
Haywood et al. 2000 
4 45 
56 
58 
58 
62 
Sle2 
Lbw2 
Lmb1 
Sles2 
Nba1 
NZM 
NZB/NZW 
MRL 
NZM 
NZB/NZW 
 
1p35-34 
1p35-34 
1p35-34 
1p36-35 
Morel et al. 1994 
Kono et al.1994 
Vidal et al. 1998 
Morel et al. 1999 
Drake et al. 1994 
5 20 
41 
81 
Sle6 
Lmb2 
Lmb3 
NZM 
MRL 
NZB/NZW 
4p16 
4p13-12 
Morel et al. 1999 
Vidal et al. 1998 
Kono et al.1994 
6 65 Lbw4 NZB/NZW 12p13-12 Kono et al.1994 
7 15 
23 
28 
51 
Sle3 
Lbw5 
Lmb3 
Nba3 
NZM 
NZB/NZW 
MRL 
NZB/NZW 
19q13.1-13.2 
19q13.3-13.4 
Morel et al. 1994 
Kono et al.1994 
Vidal et al. 1998 
Drake et al. 1995 
9 1 Sles4 NZM 11q22 Morel et al. 1999 
10 41 Lmb4 MRL 12q22-24 Vidal et al. 1998 
11 29 Lbw8 NZB/NZW 5q23-35 Kono et al.1994 
17 19 
19 
23 
Lbw1 
Sles1 
H-2 
NZB/NZW 
NZM 
NZM 
6p21.3 
6p21.3 
6p21 
Kono et al.1994 
Morel et al. 1999 
Morel et al. 1994 
18 47 Lbw6 NZB/NZW  Kono et al.1994 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aLocations and bsyntenic regions identified from the Mouse Genome Database (MGD), Mouse Genome 
Informatics Web Site, The Jackson Laboratory, Bar Harbor, Maine. World Wide 
WebURL:http://www.informatics.jax.org/). [October 1].  
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8.2. Human genetics of SLE 
 
8.2.1. Association studies in SLE 
 
8.2.1.1. HLA association  
 
The first report of an association between SLE and HLA in man was published by Grumet et 
al. in 1971. Since then, several studies have confirmed this observation and indicated that 
HLA-DR2 and HLA-DR3 separately confer 2- to 3-fold relative risk for the development of 
SLE in European-Caucasian populations. On the other hand, in African-Americans HLA-DR2 
and HLA-DR7 have been associated with SLE. There are also established associations 
between SLE and HLA-B7, -B18, -DQAi, -DQB1, -DQ3 and –DR7 (Arnett 1997). Variation 
among associated alleles and haplotypes (HLA often shows LD) between populations, and 
within a population with different ethnics groups, exist. In different subphenotypes of SLE, 
there are strong associations between the production of specific autoantibodies and various 
HLA–DQ alleles (Bell and Maddison 1980); the heterozygous combination DQw2.1/DQw6, 
for example, has been shown to correlate closely with the production of autoantibodies to 
Ro/SS-A and La/SS-B, and importantly this association is present in both European and 
African –American populations. Related to these findings, the production of low levels of 
anti-Ro (in the absence of anti-La) in Europeans was associated with DR2 and DQw6, which 
are in linkage disequilibrium, whereas the same LD haplotype was associated to production of 
anti-Sm in African-American SLE patients. HLA-DQ allelic associations have also been 
associated with antiphospholipid antibodies (anticardiolipin antibodies and/or the lupus 
anticoagulant), anti-dsDNA, and in a subset of patients with lupus nephritis. (Vyse and Kotzin 
1998) Interestingly, some HLA alleles may be protective; HLA-B40 among an Australian 
population and HLA-DR4 in a Japanese population are suggested to decrease the risk of 
developing SLE (Kameda et al. 1982; Whittingham et al. 1983). 
 
8.2.1.2. Complement components 
 
The complement system consists of ~20 plasma proteins that function in defending the body 
against infections and mediate the clearance of necrotic and apoptotic cell debris from the 
body.  
Deficiency states within the complement system increase the risk of SLE. Around 90% of 
individuals with C1q deficiency and 75% with C4 deficiency develop SLE, while less than 
20% of C2 and C3 deficient individuals develop this disease (Sturfelt 2002). C1q deficiency is 
a very rare disorder causing a particularly severe form of SLE, with glomerulonephritis and 
skin manifestations, beginning in the first or second decade of life (Bowness et al. 1994). 
Some patients with C1q deficiencies die from meningitis or recurrent infection. Both 
complete and partial C1q deficiencies have been reported among SLE patients (Kelly et al. 
2002).  
Deficiencies in complements C2 and C4 are associated with a mild form of lupus (Vyse and 
Kotzin 1998). These patients show allelic variations in the form of C2A/C2B and C4A/C4B. 
The deficiency of these complement components can be either partial or complete. Partial C4 
deficiency is common; the C4A null allele (C4A*Q0) is associated with almost every SLE 
population studied today, with increased frequencies specifically in patients of the African-
American and European–American origin (Arnett and Reveille 1992). The C4A null allele is 
in linkage disequilibrium with HLA-DR3, but is also seen in populations without HLA-DR3 
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association, hence indicating that the C4 allele may be an independent risk factor for SLE 
(Fielder et al. 1983; Kelly et al. 2002) Complete C4 deficiency (four null alleles) is rare, and 
such cases manifest an early age of SLE onset, renal disease, and anti-Ro without anti-DNA 
autoantibodies (Ratnoff 1996). 
C2 deficiency is the most frequent complement deficiency seen in man (Kelly et al. 2002). 
Patients with this deficiency manifest a mild form of the disease, with cutaneous and articular 
involvement. These patients often lack pleuropericardial, neurologic or renal manifestations. 
Photosensitivity or the presence of anti-Ro autoantibodies can be associated to C2 deficiency 
(Kelly et al. 2002). 
 
8.2.1.3. Fc? receptors  
 
The Fc?-receptors Fc?RI (CD64), Fc?RII (CD32), and Fc?RIII (CD16) function to bind and 
clear IgG antibodies and IgG-containing immune complexes from the circulation. Each of 
these receptor families contains multiple genes and alternative splicing variants. In addition, 
there are allele variants with distinct functional capacities to phagocytes (Salmon et al. 1992). 
Fc?RIIA association with SLE has been directly demonstrated (Salmon et al. 1996). Fc?RIIA 
occurs in two allelic forms, with either an arginine (R131) or a histidine (H131) at position 
131 in the second Ig-like domain. The H131 allele can only efficiently bind IgG2 on 
monocyte-magrophages with optimal clearance of IgG2-immune complexes in the 
homozygous state (Salmon et al. 1992). The skewed distribution toward a homozygous 
R131/R131 genotype has been associated with SLE, especially with nephritis, both in 
European (Duits et al. 1995; Dijstelbloem et al. 2000) and among African-American patients 
(Salmon et al. 1996). However, controversial results, reporting no association with the 
R131/R131 genotype, in these ethnic groups also exist (Botto et al. 1996; Salmon et al 1996; 
Manger et al. 1998, Oh et al. 1999). This can be due to either genetic variation in different 
ethnic groups, to admixture or to artifact. 
Similar to Fc?RIIA, skewing of the frequencies of allelic variants of Fc?RIIIA and Fc?RIIIB 
have been observed among SLE patients (Kelly et al. 2002). The Fc?RIIIA receptors 
contribute in cell death and are found on the surface of natural killer cells, mononuclear 
phagocytes, and renal mesangial cells (Radeke et al. 1994). Various Fc?RIIIA alleles are 
associated with lupus nephritis, but are also seen in patients with arthritis and serositis. 
Fc?RIIIB are selectively expressed on neutrophils and have low affinity binding to IgG. 
Individuals with a N2/N2 genotype have decreased capacity to mediate phagocytosis than 
those with a N1/N1 genotype (Salmon et al. 1990). 
The genes encoding the Fc? receptors in humans are located on chromosome 1q22-24. 
Interestingly, the loci linked to nephritis in New Zealand hybrid mice (Nba2/Sle1) is also 
loated on distal mouse chromosome 1, and includes the mouse orthologue of human FCGR2A 
gene, Fcgr2. 
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8.2.1.4. Other genes 
Weak association with cytokines, mannose binding protein (MBP), and apoptosis genes have 
been identified in patients with SLE, but additional studies are needed to further determine 
these genes as susceptibility loci. The susceptibility genes associated with human SLE and 
their location are listed in Table 3.  
MBP is a complement regulatory protein structurally analogous to C1q, and is capable of 
activating the classical complement pathway (Kelly et al. 2002). Cytokines are important in 
modulating humoral and cellular immunity, and various abnormalities in interleukin (IL) 
production have been described in patients with SLE (Horowitz 1997). The apoptosis genes 
Fas and Fas ligand (FasL) are involved in programmed cell death or apoptosis. Mutations in 
these genes are suggested to prevent self-reactive B- and T-cells from undergoing apoptosis, 
thereby leading to autoimmunity (Tan and Arnett 1998). Conversely, Bcl-2 appears to prolong 
the survival of B- and T-cells, leading to the development of SLE-like disease in transgenic 
mice (Strasser et al. 1990). 
Table 3. Genes associated with systemic lupus erythematosus 
Gene        Chromosomal location 
 
Major histocompatibility complex class II (DR and DQ) 6p21.3 
Complement components 
       C1q (homozygous deficiency)    1q36.3 
       C1r (homozygous deficiency)    12p13 
       C1s (homozygous deficiency)    12p13 
       C4  (partial deficiency; C4A null alleles,  
                                  C4B null alleles)  12p13 
       C2  (homozygous deficiency)    6p21.3 
       Complement receptor-1 (CR1)    1q23 
Mannose binding protein (MBP)    10q11.2 
Cytokines 
       Tumor necrosis factor (TNF?)    6p21.3 
       IL (interleukin)-10     1q31-32 
       IL-6?       7p21-15 
       IL-1 receptor antagonist     2q14.2 
Fc?RII        1q23-24 
Fc?RIII       1q23-24 
Apoptosis genes 
       Bcl-2       18p21.33 
       FasL       1q23 
       Fas?       10q24.1  
Adapted from Tan and Arnett 1998 
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8.3. Linkage studies in SLE 
8.3.1 Unstratified studies 
To date, six genome-wide scans using SLE as the phenotype, without stratification for 
subphenotype, have been conducted in different ethnic groups using different analytical 
approaches (Gaffney et al. 1998 and 2000; Moser et al. 1998; Shai et al. 1999; Gray-McGuire 
et al. 2000, Lindqvist et al. 2000). Six susceptibility loci (Table 4) surpassed the threshold for 
significance (LOD > 3.3). In addition, more than 50 suggestive susceptibility loci have been 
identified. Moreover, a number of targeted studies have been performed based on studies of 
mouse lupus (candidate regions), or to refine results obtained in genome wide scans in 
rodents. 
1q22-q24 ( Fc?RIIA) 
The first two genome wide scans in SLE were published in 1998 by two separate groups 
(Gaffney et al. 1998; Moser et al. 1998). Moser et al (1998) found significant linkage (LOD 
3.45) to chromosome 1q23, a region containing a candidate gene for Fc gamma receptor 
(Fc?RIIA). The study population consisted of 31 African-American and 55 European-
American families, which were analyzed separately as well as combined into a total collection 
of 94 pedigrees. The linkage to chromosome 1q23 was mainly detected in the African-
American pedigrees. No other linkage studies have confirmed this result. Linkage to 
chromosome 1q23-q24, however, is supported by two independent studies (Shai et al. 1999; 
Tsao et al. 2000), with evidence for linkage at marker D1S484 (Z = 2.56, p = 0.006 and p = 
0.019 respectively). This marker lies 3 cM distal to Fc?RIIA. In addition, Gray-McGuire et al. 
(2000), using many of the same pedigrees (Moser et al. 1998), found evidence of the 
suggestive linkage to chromosome 1q23-q24 (LOD = 2.47, p = 0.01) applying different 
methods. Case-control association studies in human SLE and linkage studies with mice 
(discussed earlier) both corroborate the observed linkage to Fc?RIIA. 
6p11-p21 (HLA region) and 16q13 
Gaffney et al. (1998) published their first genome wide scan using 105 sib-pair families 
(cohort 1), mostly of Caucasian origin (84 families). By utilizing multipoint non-parametric 
methods, they were able to demostrate significant linkage of SLE to HLA loci at 6p11-p21 
(D6S257, LOD = 3.9), and to 16q13 (D16S415, LOD = 3.64). Later, the same group recruited 
82 additional sib-pair families (cohort 2), again mainly Caucasian (Gaffney et al. 2000). The 
two patient cohorts were first analyzed separately. Different linkage results were obtained for 
each patient cohort. Nevertheless, combined multipoint analyses again demostrated evidence 
for linkage at D6S426 (HLA region), with an overall LOD score of 4.19 (resulting purely 
from cohort 1) and 16q13 (D16S415, LOD = 3.85), hence suggesting the contribution of these 
two loci to SLE susceptibility.  
Two independent genome wide scans (Lindqvist et al. 2000; Shai et al. 1999) demonstrated 
linkage to HLA region at markers D6S273 (LOD = 1.54) and D6S276 (NPL = 1.6). 
Moreover, as discussed earlier, association studies in man (HLA association, complement 
components) and linkage studies in mice, have indicated evidence for HLA contribution in the 
development of SLE. Finally, the human HLA region is synthetic with mouse MHC, in the 
proximity of which lies the most potent suppressive modifier gene, Sles1, which suppresses 
the autoimmune phenotype of murine Sle1 (Wakeland et al. 2001). 
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Linkage of SLE to the 16q13 region is supported by Shai et al. (1999), who observed linkage 
at marker D16S3136 (NPL = 2.14, p = 0.017). The 16q13 region contains a susceptibility 
gene, nucleotide-binding oligomerization domain (NOD2), for Crohn´s disease, which is an 
autoimmune inflammatory disease (Hugot et al. 2001). In addition to SLE, there is evidence 
for linkage to 16q13 in other autoimmune diseases,  including type I diabetes (Becker et al. 
1998), suggesting that apparent sharing of susceptibility loci between various autoimmune 
disorders may be important for genetic predisposition to autoimmunity in general. 
1q41-q44 (PARP) 
This locus was originally identified by Tsao et al. (1997) as a candidate region homologous to 
mouse lupus susceptibility. A significant increase in allele sharing (over 0.5) in 52 SLE- 
affected sibpairs from three ethnic groups (Caucasians, Asians and African-Americans) 
provided evidence for linkage at 1q41-q42. This region contains several candidate genes, of 
which poly ADP-ribose polymerase (PARP) gene was identified to be that most associated 
with SLE among affected offspring in 124 families (Tsao et al. 1999). The 1q41-q42 locus 
showed also strong evidence for linkage also in the primary genome-wide scan by Moser et 
al. (1998) (D1S3462, LOD = 3.5), with a dominant inheritance model. Recently, Graham et 
al. (2001) localized a candidate gene (estrogen-related receptor gamma, ESRRG) in this 
region centromeric to PARP. The patients were primarily those analyzed in the combined 
genome-wide scan by Gaffney et al. (2000), where only a weak linkage result from cohort 1 at 
1q41( D1S299, LOD = 1.33) was identified. With the addition of 24 sibpairs (total of 210 
sibpairs) and 122 trio families, Graham et al. (2001) demonstrated significant linkage at 
marker D1S490 (p = 0.0091), suggesting that a human SLE susceptibility locus is located 
centromeric to PARP, near this marker at 1q41. Finally, in a genome-wide scan, (Shai et al. 
1999) significant linkage was found to region 1q44 (D1S2785) with NPL score 3.33 (p = 
0.0006). That study comprised 80 mixed families, multiply affected by SLE, of which linkage 
was clearly found only among Mexican-Americans. Even though the linked locus resides 
distal to 1q, it supports the importance of this chromosomal region as one of the candidate 
regions for a susceptibility gene for SLE, at least in some ethnic groups. 
2q37 (PDCD1) 
Significant linkage for SLE susceptibility to chromosome 2q37 (D2S125, LOD = 4.24) was 
identified in a genome-wide scan using a homogeneous population from Iceland and Sweden 
(Lindqvist et al. 2000). The two populations were first analyzed separately. The strongest 
evidence for linkage in Icelandic families occurred at 4p13-p15 (D4S1627, Z = 3.2), and in 
Swedish families at 2q37 (D2S125, Z = 2.18). When the families were combined, the LOD at 
D2S125 increased to 4.24. The LOD with the combined data set for chromosome 4 remained 
unchanged. Although no other studies have confirmed the linkage at 2q37, this region 
contains a locus for programmed cell death 1 gene (PDCD1), which is considered a good 
candidate gene for SLE. In fact later, in a large multinational study (2,510 individual) 
(Prokurina et al. 2002), one intronic single nucleotide polymorphism (SNP) in PDCD1 was 
found to associate with development of SLE in Europeans (p = 0.0001) and Mexicans (p = 
0.009). The PDCD1 gene is an immunoreceptor, a member of the immunoglobulin family, 
which is known to regulate peripheral self-tolerance in T-and B-cells. Mice lacking Pdcd1 
develop a SLE-like disease (Prokurina et al. 2002). The SLE associated SNP in PDCD1 alters 
a binding site for runt-related transcription factor1 (RUNX1, also called AML1), suggesting a 
mechanism through which it can contribute to the development of SLE in humans (Prokurina 
et al. 2002). 
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4p15.2-p16 
Evidence for moderate or suggestive linkage to 4p15-p16 has been obtained at least in three 
independent genome-wide scans. Moser et al. (1998) identified suggestive linkage at D4S403 
(LOD = 2.18) in European-American families with a dominant model of inheritance. The 
same marker had moderate linkage (LOD = 1.31) in the combined data set (cohort 1 and 2) of 
Gaffney et al. (2000). Finally, Lindqvist et al. (2000) presented evidence of linkage to 
D4S1627 (LOD = 3.2) in six Icelandic families. The 4p15.2-p16 region contains a number of 
interesting candidate genes, including human lymphocyte differentiation antigen (CD38), and 
bone marrow stromal cell antigen 1 (BST1) (Wakeland et al. 2001).  
Recently, a genome-wide scan of 126 multiplex pedigrees, including 469 sibling pairs and 
175 affected relative pairs, revealed supporting evidence for linkage on chromosome 4p 
(Gray-McGuire et al. 2000). The pedigrees used in this study were essentially the same as 
those included in the original genome wide scan of Moser et al. (1998). The maximun LOD of 
3.84 (p = 0.003) was identified at marker D4S2366 in European-American families. 
We have here described those identified regions from six independent genome wide scans that 
have shown a significant evidence of linkage in patients with SLE (Table 4). In addition to 
these reported regions, there are several additional loci that show weaker, but suggestive, 
evidence for linkage in SLE. Those regions with at least nominal evidence for linkage in at 
least two independent family collections are listed in Table 5. 
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Table 4. Regions showing significant linkage to SLE in six genome wide scans 
 
 
Locus LOD/Z Marker No. of families,  
SLE patients 
Origin of families  Reference 
1q22-q24 
1q41-q43 
 
 
LOD = 3.45a  
LOD = 3.5a 
 
(Fc?RIIA)  
D1S3462  
 
94    families 
220  patients 
55  EA families 
31  AA families 
8    Other 
Moser et al. 1998 
(OMRF) 
 
1q44 
 
 
 
NPL = 3.33b 
(p = 0.0006) 
 
D1S2785 
 
80    families 
188  patients 
 
43  MA families 
37  EA families 
 
Shai et al. 1999 
(USC) 
 
2q37 
 
 
Z =  4.24a 
 
 
D2S125 
 
 
17   families 
44   patients 
 
 
11  Swedish 
6    Icelandic 
 
Lindqvist et al. 
2000 
(Uppsala) 
 
 
4p15-p16 
 
LOD = 3.84c 
 
D4S2366 
 
126 families 
175 ARPs 
 
 
 
112 EA families 
52  AA families 
11  Other 
 
 
Gray McGuire et 
al. 2000 
(OMRF) 
 
6p11-p21 
16q13 
 
 
LOD =  4.19b 
LOD = 3.85b 
 
 
 
D6S426  
D16S415 
 
187 families 
399 patients 
 
 
148 EA families 
17   AA families 
13   Hispanic 
9     Other 
 
Gaffney et al 
1998;  
Gaffney et al. 
2000 
(Minnesota) 
Analytical methods used for established linkages:  a model-based  two-point linkage, b non- parametric 
multipoint linkage, c conditional logistic regression technique with affected relative pairs (ARP). EA = 
European-American, AA = African-American, MA = Mexican-American 
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Table 5.  Regions demonstrating “suggestive”* linkage in SLE in at least two independent 
studies†. Adapted from a study by Gaffney et al. (2000) 
 
Locus 
 
LOD (marker) 
Minnesota 
LOD (marker) 
OMRF  
LOD (marker) 
USC 
LOD (marker) 
Uppsala 
1q31  2.04   1.61 (D1S1660) 
2q32-35 1.45 (D2S126) 2.09 (D2S1391)   
4p13-15 1.31 (D4S403) 2.18 (D4S403)   
6q26-27  2.04 (D6S1027)  1.35 (D6S503) 
9p24-21  2.08 (D9S925)  2.27 (D9Sgata62f03) 
11q23  2.10 (D11S2002)  1.15 (D11S1998) 
13q31-32 1.02 (D13S170) 2.50 (D13S779)   
14q11-23 2.81 (D14S276) 2.21 (D14S742) 2.02 (D14S258)†† 1.15 (D14S592) 
15q26 1.07 (D15S127)   1.95 (D15S657) 
19q13.1  2.05 (D19S246)  2.06 (D19S246) 
20p12-13 2.62 (D20S186)  1.13 (D20S115)‡  
20q11-13 1.64 (D20S119) 2.49 (D20S481)   
*Recommended criteria for suggestive linkage in genome-wide scan for a complex disease (LOD>1.9 
for complex pedigrees, LOD > 2.2 for sib pairs (Lander and Kruglyak, 1995). † shown are markers 
meeting criteria for each interval. Supporting evidence (LOD > 1.5) from an independent family 
collections is also shown if present. ‡ Z scores were converted to LOD scores by equitation: LOD = 
A2/Zln10 (Kong and Cox, 1997). Lod = Logarithm of odds. OMRF = Oklahoma Medical Research 
Foundation. USC = University of Southern California. ††= NPL (non-parametric linkage) score. 
 
 
 
 
8.3.2. Stratified studies 
 
In recent genome-wide scan studies, pedigrees have been stratified according to clinical 
manifestations. The aim is to achieve genetically and clinically homogeneous sets of families, 
and to increase the power to detect susceptibility genes for different subphenotypes of SLE. 
At least 11 regions have been significantly linked to SLE using both model-based and 
nonparametric approaches with different phenotypes (Table 6). The families analyzed in these 
stratified studies were mostly the same as those genotyped in the primary genome wide scan 
using the SLE phenotype (Moser et al. 1998; Gaffney et al. 1998 and 2000; Shai et al.1999; 
Gray-McGuire et al. 2000; Lindqvist et al. 2000). 
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Table 6. Regions showing significant linkage in genome-wide scans with different SLE          
subphenotypes. 
 
LODPAL= multipoint conditional logstic regression on affected relative pairs (Olson 1999),  
Subphenotype Locus LOD/NPL Marker Candi-
date 
gene 
Material Author 
 
Vitiligo 
 
 
17p13 
 
LOD = 3.64  
(NPL = 4.02) 
 
 
D17S974-
D17S1298  
 
 
SLEV1 
 
16 EA families 
 
Nath et al. 
2001 
 
Neuropsychiatric 
Manifestations  
(Seizures and 
psychosis) 
 
 
4p16 
 
 
 
LOD = 5.19 (EA) 
(NPL = 3.12 (EA)) 
 
 
 
D4S3007  
 
 
SLEB3 
 
23 EA families 
20 AA families  
 
Nath et al. 
2002 
 
Self-reported 
rheumatoid 
arthritis 
 
 
5p15.3 
 
LOD = 6.2  (EA) 
(NPL = 5.64 (EA) ) 
 
D5S2505  
 
 
SLER1 
 
 
14 EA families  
19 AA families  
3   OE families 
 
Namjou et 
al. 2002 
 
Anti-double 
stranded DNA 
(dsDNA) 
antibodies 
 
 
19p13.2 
18q21.1 
 
 
LOD = 4.93 (EA) 
LOD = 3.40 (AA) 
 
 
D19S714  
D18S858 
 
 
SLED1 
SLED2 
 
 
37 EA families  
29 AA families  
5   OE families  
 
Namjou et 
al. 2002 
 
Hemolytic 
anemia 
 
 
11q14 
1q24 
 
LOD = 4.5 (AA) 
LODPAL = 4.0 * 
(EA) 
 
D11S 2002  
D1S1589 
 
SLEH1 
 
17 EA families  
16 AA families  
2   HP families 
 
Kelly et al. 
2002 
 
Renal disease 
 
 
 
 
10q22.3 
11p15.6 
 
LOD = 3.16 (EA) 
LOD = 2.58 (AA) 
 
D10S2470  
D11S1984 
 
 
SLEN1 
SLEN3 
 
 
31 EA families  
40 AA families  
 
 
 
Quintero-
Del-Rio 
 et al. 2002 
 
 
Nucleolar 
antinuclear 
antibodies 
(ANA) 
 
 
11q14 
  
LOD = 5.62 (AA) 
 
D11S2002 
 
SLEH1 
 
12 AA families 
14 EA families 
1   NA family 
 
Sawalha et 
al.2002 
 
Thrombo-
cytopenia 
 
1q22-23 
11p13 
 
LOD = 3.71 (All) 
LOD = 5.72  (AA) 
 
D1S1677  
D11S1392 
  
38 mixed 
     pedigrees 
13 AA families 
 
Scofield et 
al. 2003 
* = surpasses the suggested threshold for significant linkage (LOD > 3.3, Lander et Kruglyak 1995).  
AA = African-American; EA = European-American; OE = other ethnic families; HP = Hispanic; NA = 
Native American 
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8.4. Overlap with other autoimmune disorders 
SLE belongs to the group of autoimmune diseases which are caused by an immune response, 
humoral or cell mediated, against self antigens. Complex interactions of genetic and 
environmental factors play a role in their background. Collectively, autoimmune diseases are 
estimated to affect 4 to 5% of the population, and females are generally more often affected 
than males (Vyse and Todd 1996). Examples of autoimmune diseases include type I diabetes, 
rheumatoid arthritis, Hashimoto´s thyreoiditis, and myastenia gravis. There is evidence for 
both familial clustering of different autoimmune diseases (Lin et al. 1998), and for 
coexistence of several autoimmune diseases within the same individual (Lorber et al. 1994). 
Moreover, recent genome mapping studies in complex diseases have led to identification of 
susceptibility loci for a number of autoimmune diseases. The non random clustering of 
identified loci has been observed in both animal models (Vyse and Todd 1996) and human 
autoimmune diseases (Becker et al. 1998), suggesting that clinically distinct autoimmune 
diseases may be controlled by a common set of susceptibility genes (Becker et al 1998). 
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AIMS OF THE STUDY 
 
 
1. To find multiplex SLE families in Finland and to clinically characterize the affected 
patients as compared to patients with sporadic SLE. 
 
2. To study the associaton of aPL with thrombotic events in patients with SLE.  
 
3. To conduct a genome-wide search for SLE susceptibility loci in multiply affected 
pedigrees using linkage mapping. 
 
4. Fine-map the genomic regions identified in the genome wide scan in patients with 
SLE. 
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MATERIALS AND METHODS  
 
 
1. Patient recruitment 
 
The recruitment of patients began in 1995 at two University hospitals; Helsinki and Kuopio 
(in central eastern Finland, Fig. 4). Patients treated in these hospitals during 1992 to 1995 
were identified from the hospital registries and were contacted personally or by mail. 
Additionally, patients registered by the Lupus Foundation of Finland, and patients answering 
an advertisement published in patient bulletins, were recruited. The second recruitment phase 
in 1996 targeted families multiply affected by SLE. Physicians treating SLE patients (mainly 
rheumatologists) from of 21 hospitals in Finland were contacted. A letter was sent to all 
patients treated in these hospitals during 1993 to 1996. All patients were asked whether they 
had relatives or family members diagnosed with SLE or a related connective tissue disease. 
Patients with a positive family history were asked to participate in the study and informed 
consent was obtained. According to the prevalence of SLE in Finland (Helve 1985), we 
succeeded in contacting roughly 1200 of 1500 available patients by phone or by mail during 
the two phases of recruitment, accounting for approximately 85% of all Finnish SLE patients 
requiring hospital-based treatment. In Finland the diagnosis of SLE is practically always 
assessed in hospital by a specialist.  In most of the identified families there was only a single 
SLE patient (sporadic cases) and these could not be used for a linkage study. 
 
Blood samples from patients and their relatives were obtained from a total of 252 families, of 
which 53 were multiply affected by SLE (multiplex families), and the rest was families of 
sporadic patients. Patients were interviewed by the same physician (H.J.) either personally or 
by phone, and the case records from the hospitals were reviewed. All patients met the 
American College of Rheumatology criteria for the diagnosis of SLE (Tan et al. 1992).  
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2. Study subjects 
 
In Study I the clinical characteristics of 113 patients from 53 families were evaluated. Forty-
six out 53 multiplex families had 2 affected members. The relationships in 2 affected families 
were: 17 sibpairs, 10 parent/offspring, 7 aunt/niece or aunt/nephew-pairs, three female cousin-
pairs, two female monozygotic twin pairs, one dizygotic twin pair. In 6 families, affected 
pedigree members were distant relatives. Examples of such families are shown in Fig. 2. 
         
 
 
Fam A        Fam B      
                                                              
  
 
Fig.2  Examples of relationships in families where the 2 affected members were more 
distantly related to each other.          = affected female;       = non-affected male;       = deceased 
                               
 
 
Families with three affected pedigree members 
 
Seven of 53 multiplex families had 3 affected pedigree members. Patients in these families 
were mostly first-degree relatives (Fig.3, Fam 1, 2 and 3). Two of the families had both first- 
degree and more distant relatives (Fig.3, Fam. 4 and 5).
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      Fam. 1      Fam. 2                                    Fam. 3 
                                                                    
 
 
 
 
   
 
 
 
  
 
 
 
      Fam.4      Fam.5 
 
  
 
   
                                                                    
Fig 3. Examples of relationships in families with three SLE patients.  
  = affected male;       = affected female;      = non-affected;       = decased 
 
 
In Study II, we investigated one SLE subphenotype, antiphospolipid syndrome, using serum 
samples from 89 patients with familial SLE (45 out of 53 multiplex families, described above) 
and from 203 sporadic patients.  
 
From a total of 53 multiplex families, 35 were informative for a linkage study, and were 
included in a primary genome wide scan (study III). Parents were recruited to facilitate 
phasing of chromosomes, and if unavailable, an unaffected sibling was sampled to allow 
reconstruction of parental genotypes. In total, 73 SLE patients and 96 healthy relatives (169 
individuals altogether) were included in this linkage study. In 32 of 35 families there were 2 
affected family members. The most common combination was sister/sister (16 families), 
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followed by aunt/niece (8 families). Three families had 3 SLE patients. In 2 of these families, 
the affected family members were first-degree relatives (Fig 3. Fam 3), whereas in one family 
there were both second-degree (a cousin) and first-degree (mother/son) relatives (Fig 3. Fam 
4). Seven of the 73 familial cases (10%) were male, corresponding to the sex distribution of 
SLE in the general population (Hochberg 1987). 
 
For the haplotype association study (IV), 34 families originating from a restricted region in 
Savo in central eastern Finland (Fig. 4) were recruited and genotyped together with multiplex 
families using dense marker maps. According to taxation records, the Savo area (Fig. 4) was 
settled in late 1600´s by no more than 1000 people (229 houses), whereafter the population 
has grown, virtually without immigration, to its current size of 200 000. Due to the population 
history of Northern Savo, we anticipated reduced genetic heterogeneity of the probands in 
these families, ideal for a linkage disequilibrium study. Moreover, this region is already 
known for a previously characterized founder effect, for the MLH1 susceptibility gene for 
colon cancer (Nystrom-Lahti et al. 1994). 
 
Three of the finemapped Savo families were multiply affected by SLE, and hence had been 
already in the primary genome-wide scan. The remainder of the 31 families were simplex 
trios, mostly including mother, father and offspring (in 13 families), or with only one of the 
parents available (8 families) for haplotype reconstruction. Consanguinity was investigated 
from population records back the late 18th century (in most families back to the mid 19th 
century), and none was observed between the families. Altogether, 66 families with 262 
individuals were included in this fine-mapping and association study.  
 
Fig 4. The location of Savo region in central eastern Finland 
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3. Control individuals 
 
In Study I, patients from sporadic SLE families were used as a control for comparison of 
clinical manifestations and laboratory findings. Control patients were chosen in alphabetical 
order and matched by sex, age and duration of SLE symptoms. 
 
In Study II, serum samples from 111 people (mean age 56.6 years, SD 19.9 years, range 14 to 
93 years, males 44%) with no previously diagnosed chronic autoimmune diseases were used 
as controls.  The cut-off levels for positivity were set at the 95th percentile for IgG-, IgA-, and 
IgM-aCL, anti-protrombin, and anti ?2-GPI. For antibodies to ox-LDL, the upper reference 
value was set at the 95th percentile for 200 healthy blood donors attending the Finnish Red 
Cross Blood Transfusion Service. 
                                                                                                                                                                              
For the association study (IV) healthy spouses within families were used as controls. 
 
 
4. PCR amplification 
 
Genomic DNA (20 ng) prepared from peripheral blood samples, was amplified in 5 ?l PCR 
assays using 0.33 ?M of fluorescently labeled primers and 0.2 units of AmpliTaq Gold DNA 
Polymerase. Prior to the PCR assays, the DNA was distributed to 384-well microtiter plates 
using a Hydra-96 microdispenser (Robbins Scientific, Sunny Vale), whereafter the DNA 
solution was dried. The PCRs were assembled using a TECAN Genesis 150/8 robotic sample 
processor (TECAN Ag, Hombrechtikon, Switzerland), and run in a Dual 384-Well GeneAmp 
PCR System 9700 (PE Biosystems, Foster City, CA). Following an initial heating step of 12 
min at 95?C, 30 cycles of PCR were performed (10 cycles of 30 sec at 95?C, 30 sec at 55?C, 
and 30 sec at 72?C, and 20 cycles of 30 sec at 89?C, 30 sec at 55?C and 30 sec at 72?C).  
 
 
5. Genotyping of microsatellite markers 
 
The amplified PCR fragments were multiplexed (on average 13 markers in a pool), and then 
separated using capillary array electrophoresis (MegaBACE 1000, Amersham 
Pharmaceuticals, Amersham, UK). The capillary runs were analyzed using the Genetic 
Profiler 1.1 software (Amersham Pharmaceuticals), which performs automatic sizing and 
allele calling. All electropherograms were manually reviewed prior to analyses.  
 
Microsatellite markers from the Linkage mapping set MD-10 (PE Biosystems) were used in 
the primary genome-wide scan. Of the 400 markers in the linkage mapping set, we retrieved 
data from 388 markers. The average intermarker distance was 9.73 cM. The data contained 
six gaps of 20 to 26 cM. To cover the gaps, and to fine-map the susceptibility region for SLE 
obtained in Study III, a total of 73 extra markers were genotyped, combined with the primary 
genome wide scan and re-analysed. The final density between markers in fine mapping 
regions (Study IV) was < 1cM. All markers were selected from Marshfield genetic maps 
(http://research.marshfieldclinic.org/genetics/) and the marker order for fine mapping was 
verified using the NCBI sequencing database (http://www.ncbi.nlm.nih.gov) and UCSC 
human genome assembly (http://genome.ucsc.edu). The marker order was in accordance with 
the deCode genetic linkage map (Kong 2002). For multiplex families, Mendelian errors were 
checked using the Pedmanager and PedCheck software (O´Connel et al. 1998), and overall 
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genotype frequencies were tested for Hardy-Weinberg equilibrium. The results were analyzed 
using non-parametric multipoint linkage analysis with the Genehunter software (Kruglyak et 
al. 1996). 
 
 
6. Assays for aPL antibodies and ox-LDL 
 
6.1. Anti-cardiolipin ELISA 
 
Anti-cardiolipin antibodies were detected according to a previously decribed ELISA method, 
with the exception that 10% bovine serum was used as the blocking solution (Vaarala et al. 
1993) 
  
6.2. Anti-protrombin ELISA 
 
A method for detection of anti-prothrombin has been previously described in detail (Puurunen 
et al. 1996). Briefly, irradiated polystyrene plates (Combiplate® Enchanced Binding, 
Labsystems, Helsinki, Finland) were coated with human prothrombin (Sigma Chemical Co., 
St.Louis, MO) at a concentration of 10µg/ml in PBS, 100µl per well, and incubated overnight 
at +4oC. The plates were washed with 0,5% Tween-PBS before blocking with 3% gelatin in 
PBS for 1 h at room temperature. Serum samples were diluted 1:50 in 0.3% gelatin-PBS and 
incubated for 1.5 h at room temperature. Alkaline phosphatase-conjugated rabbit F(ab´)2 
fragment anti-human IgG antibodies (Jackson Immunoresearch Laboratories, West Grove, 
USA), diluted 1:2000 in 0.2% human serum albumin (HAS)-PBS, was added and incubated 
for 1 h at room temperature. P-nitrophenyl phosphate (Sigma Chemical Co), 1mg/ml in 
carbonate buffer, pH 9.8, was used as a substrate and incubated for 30 min at room 
temperature. The absorbance was measured by an optical reader at 405 nm.  
 
6.3. Anti-ß2-glycoprotein I (GPI) 
 
The assay was performed similarly to the anti-prothrombin ELISA except that the 
concentration of ß2-GPI used for coating was 5 mg/ml and the samples were diluted 1:200. 
 
6.4. Antibodies to ox-LDL 
 
IgG class antibodies to malondialdehyde-modified LDL were measured using an ELISA 
method described previously (Vaarala et al. 1993).   
 
 
7. Statistical analyses 
 
7.1. Linkage analysis 
 
Linkage analyses were carried out using non-parametric multipoint analysis (NPL) with the 
Genehunter software (v.s. 2.0 for chromosomes 1-22, and v. 1.3 for the X-chromosome) 
(Kruglyak et al. 1996)  
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7.2. Simulation 
 
The thresholds of significant and suggestive linkage are defined by Lander and Kruglyak 
(1995) as the NPL score levels corresponding to the random occurrence of one false positive 
hit per 20 genome scans (p = 0.05 per genome scan), and one false positive occurrence per 
genome scan, respectively. For any given set of families and markers, the exact levels of 
significant and suggestive NPL scores can be determined by computer simulation (Laitinen et 
al. 2001).  To get an estimate of the global p-value, we performed allele dropping simulations 
under a null hypothesis of no linkage. The simulations consisted of 200 iterations (Laitinen et 
al. 2001). In each iteration, founder alleles were drawn from the estimated allele frequency 
distributions, and missing genotypes were introduced to the same positions as in the real data. 
As a result, we obtained an empirical distribution for the NPL scores corresponding to 
suggestive and significant linkage (Lander and Kruglyak, 1995).  
 
7.3. Haplotype association analysis 
 
Haplotype Pattern Mining (HPM) is an association analysis based on data mining 
methodology (Toivonen et al. 2000, Sevon et al. 2001). It is ideal for complex diseases, as no 
inheritance model for the disease is required. The statistical model is non-parametric. The 
method searches for combinations of marker alleles which are more frequent in disease-
associated chromosomes than in control chromosomes. The method allows gaps, missing, and 
erroneous data in haplotypes, maximizing the length of the shared haplotype. The number and 
the length of gaps can be set by the user. The capacity to handle high proportions of 
phenocopies makes the method promising for complex disease mapping.  
 
In the present study, independent trios from the pedigrees were haplotyped using an in-house 
software tool designed for this purpose (Petteri Sevon, unpublished software). The maximum 
length of pattern (markers), maximum number of gaps and minimum X2 for a pattern were 
defined. To compensate for variable marker densities and marker information contents, a total 
of 10,000 permutations were run to obtain empirical p-values (Toivonen et al. 2000). 
 
7.4. Transmission Disequilibrium Test (TDT) 
 
The TDT was introduced as a method for identification of linkage between complex disease 
and a genetic marker in the presence of association (linkage disequilibrium) (Spielman et al. 
1993). TDT uses data from families, and evaluates the transmission of an associated marker 
alleles or haplotypes from a heterozygous parent to an affected offspring. In our study, TDT 
was conducted with GENEHUNTER 2.1 (Kruglyak et al. 1996); transmissions from 
homozygous parents are excluded and cases where one parent is missing are used only when 
the genotyped parent and the proband are both distinct heterozygotes (Curtis and Sham 1995).  
 
7.5. Hardy-Weinberg equilibrium 
 
The overall genotype frequencies for multiplex families were tested for Hardy-Weinberg 
equilibrium using the program developed by Guo and Thompson (1992). Hardy-Weinberg 
equilibrium means that alleles in a population are assorting randomly among individuals in 
each generation, i.e. according to the formula p2 +2pq + q2 =1, where p and q are the 
frequencies of alternative alleles and p2 and q2 refer to the proportion of homozygotes for each 
allele and 2pq to the proportion of heterozygotes. This calculation forms an essential quality 
control procedure for genotyping. 
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7.6. Other tests 
 
The statistical tests used in evaluating the aPLs in patients with SLE were as follows: 
The sensitivity, specificity, positive predictive values and negative predictive values were 
calculated using a SPSS program. Spearman`s rank correlation was applied to study 
correlations between the different assays. The X2 test and the Fischer´s exact test, when 
appropriate, were used for the analysis of two-by-two tables.  
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RESULTS 
 
1. Characterization of clinical manifestations in patients with familial and sporadic SLE 
(Study I) 
     
The clinical manifestations and laboratory findings of 113 patients from 53 multiplex families 
and 113 patients with sporadic SLE are presented in Table 7.  
 
When multiple comparisons (Bonneferoni corrections) were taken into account, there were no 
statistical differences in clinical manifestations or laboratory findings between familial and 
sporadic cases of SLE. The mean number of ACR criteria fulfilled by familial cases was 5.2 
(range 4-9), and by sporadic cases 5.4 (range 4-9). The mean ages at onset of SLE in familial 
and sporadic cases were 30.7 years (1-66) and 29.0 years (7-59). There were no differences in 
clinical characteristics between men with familial SLE and respective controls with sporadic 
SLE. Additionally, there were no significance difference in occurrence of clinical 
manifestations between those SLE patients who were close relatives (34 affected siblings and 
20 cases of parent-offspring combinations) compared to those who were more distantly 
related (32 affecteds). 
 
Table 7. Comparison of clinical characteristics between familial and sporadic cases of SLE 
Clinical manifestation Familial SLE 
N= 113 (%) 
Sporadic SLE 
N= 113 (%) 
Difference, 
P 
Butterfly rash        52/113 (46) 57/113 (50) 0.51 
Discoid rash      6/113 (5) 13/113 (12) 0.09 
Photosensitivity           78/113 (69) 72/113 (64) 0.40 
Mouth ulcers 19/11 (17) 13/113 (12) 0.23 
Arthritis           89/113 (79) 99/113 (88) 0.08 
Pleuritis 17/113 (16) 28/113 (25) 0.07 
Pericarditis 11/113 (10) 22/113 (20) 0.036 
Nephritis     30/113 (27) 33/113 (29) 0.66 
Convulsions 10/113 (9) 4/113 (4) 0.10 
Psychosis 2/113 (2) 3/113 (3) 0.65 
AIHA  4/107 (4) 4/109 (4) 0.98 
Leukopenia 78/110(71) 74/110 (67) 0.56 
Thrombocytopenia 17/108 (16) 26/109 (24) 0.13 
dsDNA-antibodies 67/96 (70) 93/112 (83) 0.024 
FP-STS 7/42 (17) 12/48 (25) 0.33 
Antinuclear antibodies 109/111 (98) 110/112 (98) 1.0 
Deep venous thromboses 15/113 (13) 8/113 (7) 0.12 
Stroke or TIA 9/113 (8) 2/113 (2) 0.034 
AIHA = autoimmune haemolytic anaemia; dsDNA = double-stranded DNA; FP-STS = false positive 
serologic test for syphilis; TIA = trans ischemic attack.  
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2. Evaluation of one subphenotype of SLE, antiphospholipid syndrome (Study II) 
 
Study I revealed a tendency for venous thrombosis and TIA/stroke to occur in patinets with 
familial SLE. However, the differences of those between familial and sporadic SLE was not 
statistically significant. Since aPLs are known to associate with thrombosis in patients with 
SLE, we evaluated the overall prevalence of different aPLs and their association with 
thrombosis and coronary heart disease in Finnish patients with SLE and APS. Moreover, since 
the familial occurrence of aPL and APS has been described earlier (Mackie et al. 1987; Ford 
et al. 1990; Dagenis et al 1992), our particular interest was to investigate whether there was 
any clustering of aPLs within multiplex families where at least two patients had had a 
thrombosis, reflecting genetic susceptibility to the development of APS. 
 
From a total of 292 SLE patients (89 familial and 203 sporadic cases), 153 (52%) had 
antibodies detected by at least one method (Table 8). The sensitivity and specificity of each 
individual antibody assay to detect the history of thrombosis are also shown. Since it is known 
that antibodies tend to cross-react with each other, the combinations of different antibodies 
are also presented. All, except IgM-aCL, correlated rather well with each other. The 
correlation was highest between IgG-aCL and anti-prothrombin (r = 0.464) and the lowest 
between IgM-aCL and anti-ox-LDL (r = 0.032). 
 
All antibody assays, except IgM-aCL, were significantly associated with a history of any 
thrombosis (Table 9). Arterial thrombosis was clearly associated with IgG-aCL, anti-b2-GPI 
and anti-prothrombin, whereas venous thrombosis correlated significantly with all other 
assays except IgM-aCL and anti-prothrombin. Because of a small number of affected patients 
with CHD, no significant association of any antibodies and the occurrence of CHD were seen. 
 
Multiplex families 
 
The proportion of patients with familial SLE and a history of thrombosis (15/89) was not 
statistically different from that in families with sporadic SLE cases (25/203) (OR 1.4; 95% CI 
0.7-2.9). Of the 45 of 53 multiplex SLE families, there were 5 families with 3 affected 
pedigree members. In 2 of these 5 families, a thrombotic event had occurred in 2 affected 
patients. In the first family, the male proband with Klinefelter´s syndrome, had a history of 
recurrent pulmonary emboli with only marginally elevated IgA-aCL. The affected mother of 
the proband had a history of deep venous thrombosis and had an elevated level anti OX-LDL. 
Her identical twinsister, with SLE complicated by lymphoma, had elevated levels of IgG-
aCL, IgA-aCL, anti-prothrombin, and anti ß2-GPI, but no history of thrombosis.  
 
In the second family, the male proband had a history of nephrotic syndrome and multiple 
venous thromboses, but no aPL or anti OX-LDL. His mother and her cousin also had SLE; the 
former was negative for all assays and did not have thrombosis, and the latter had anti OX-
LDL with a history of deep venous thrombosis.  
 
In the remaining 40 multiplex SLE families with two affected members, there was only one 
family in which both affected patients (sisters) had a history of thrombosis. One of these 
patients was positive for all assays except IgM-aCL. Serum from the other patient was not 
available. All healthy first-degree relatives (mother, father, and one healthy sister) were 
negative for all assays. 
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Table 8.  The prevalence of antibodies to cardiolipin, prothrombin, ?2-glycoprotein I (?2-
GPI)and oxidized low-density lipoprotein (oX-LDL) in 292 SLE patients. The sensitivity, 
specificity and positive (PPV) and negative (NPV) predictive values of the tests for a history 
of thrombosis. 
 
Test  Positive
  
Thrombosis Sensitivity Specificity PPV NPV 
Any aCL isotype 
    IgG  
    IgA  
    IgM  
 
102 (35%)  
49   (17%) 
76   (26%) 
27   (9%)         
20/40 
15/40 
14/40 
5/40 
50 % 
38 % 
35 % 
13 %  
67 % 
87 % 
75 % 
91 
20 % 
31 % 
18 % 
19 % 
89 % 
90 % 
88 % 
87 % 
Antiprothrombin 58   (20%) 14/40 35 % 83 % 
 
24 % 89% 
Anti ?2-GPI 46 (16%)         14/40 35 %  87 %  30 % 89 % 
 
Anti ox-LDL 68 (23%)  4/40 35 % 79 % 21 %
  
88 %
 
Any aCL isotype + 
antiprothrombin 
 
123(42%)
  
20/40 50 % 59 % 16 % 88 % 
Any aCL isotype +  
anti ?2-GPI  
 
118 (40%) 23/40 58 % 62 %  20 % 93 % 
Any aCL isotype +  
anti ox-LDL  
 
132 (45%) 25/40 63 % 58 % 19 % 93 % 
IgG-aCL +  
anti ?2-GPI 
 
70 (24%) 19/40  48 % 80 % 27 % 91 % 
IgG-aCL + 
antiprothrombin 
 
84 (29%) 18/40 45 % 74 % 21 % 89 % 
IgG-aCL + 
anti ox-LDL 
 
94 (32%) 23/40 
 
58 % 72 % 24 % 91 % 
Anti ?2-GPI + 
anti ox-LDL 
 
91 (31%) 21/40 53 % 72 % 23 % 91 % 
Anti ?2-GPI + 
antiprothrombin 
84 (29%) 18/40  45 % 74 % 21 % 89 % 
 
Sensitivity is the rate of true positives (number of patients with thrombosis and a positive test result 
divided by the number of patients with thrombosis), specificity is the rate of true negatives (number of 
patients without thrombosis and a negative test result divided by the number of patients without 
thrombosis), PPV (positive predictive value) is the number of true positives from all positives, NPV 
(negative predictive value) is the number of true negatives from all negatives. aCL= anticardiolipin, 
IgG = immunoglobulin G, ox-LDL = oxidized low-density lipoprotein 
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 3. Identifying new susceptibility loci for SLE in multiplex families using linkage 
 mapping (Study III) 
 
The primary genome wide scan was performed with 400 highly polymorphic microsatellite 
markers (MD-10). Information was retrieved from 388 markers with an average marker 
interval of 9.73 cM. Due to the pedigree structures (i.e. missing parents), we were able to 
capture 50 to 60% of the maximum inheritance information throughout the genome. 
 
The genome scan data contained six gaps of 20 to 26 cM. The highest NPL score was on 
chromosome 6q (NPL 2.35, p = 0.01) at marker D6S441, and the two next best regions on 
chromosomes 3q (D3S1278) and 5p (D5S418) with NPL scores of 1.78 (p = 0.03) and 1.74 (p 
= 0.04). In order to establish the empirical thresholds for suggestive and significant linkage 
(i.e., NPL scores reached at random once per one or 20 genome scans (Lander and Kruglyak, 
1995)) in our data set, a simulation with 200 iterations were performed. The best observed 
NPL-score under the null hypothesis of no linkage revealed that NPL = 1.7 is reached once 
per genome scan (suggestive linkage), and the global p-value of 0.05 corresponds to NPL = 3 
(significant linkage).  Hence the 3 loci obtained in our primarily genome wide scan exceeded 
the threshold for suggestive linkage, yet none of them was significant.  
 
To verify the highest NPL scores in regions with suggestive linkage (NPL > 1.7) on 
chromosomes 3q, 5p and 6q, and to cover gaps exceeding 20 cM on chromosomes 6p (i.e. 
HLA-region), 8 and 14q (with corresponding NPL >1), we added 29 markers in these regions.  
As a result, in 2 regions with suggestive linkage, on chromosome 5p and chromosome 6q, the 
NPL scores increased with the added markers (Table 10). The overall NPL scores, including 
all genotyped markers in the genome-wide scan, are shown in Figure 5. The largest change in 
NPL scores was seen in the HLA region, where the NPL score increased from 1.2 to 2.1. The 
NPL scores for 14q increased from 1.5 to 2.2.  
 
Table 10. The linkage results in genome wide scan before and after addition of extra markers. 
 
Chro NPL
ge
NPL- scores after addition of 
ma
mosome content - scores, primary 
nome wide scan rkers 
(D3S1278, p= 0.03)  (D3S1278, p= 0.06) 
4 (D5S 3 (D5S
(D8S260, p= 0.26) (D8S260, p= 0.31) 
1-q23 (D14S288, p= 0.07) D14S587, p= 0.02) 
3q  1.78 1.55 
5p 1.7 418, p= 0.04) 2.0 418, p= 0.02) 
HLA-region 1.22 (D6S276, p= 0.11) 2.17 (D6S273, p= 0.02) 
6q25-q27 2.35 (D6S441, p= 0.01) 2.47 (D6S960, p= 0.008) 
8 0.62 0.48 
14q2 1.51 2.2 (
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Fig 5. Nonparametric multipoint linkage analyses in 35 multiply affected SLE families. All chromosomes are 
shown; those with peaks exceeding NPL=2.0 are shown in large panels (top row). NPL scores are plotted with 
solid line, scale to the left, and information content with a dotted line, scale to the right. 417 markers were 
genotyped, and the average intermarker distance was 10 cM. 
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 50
. Haplotype associations on chromosomes 6q and 14q (IV) 
tio = 5.8, 95% CI 2.6-13). The empirical association was not significant. Haplotype 1-3 was 
ilies) 
ted from Savo. Furthermore, both the 3-1 
nd 3-2-8- haplotypes, spanning 8 cM on chromosome 14q, were found in 2 families from 
eighbouring parishes in Savo.  
4
 
To verify our linkage results and to narrow down the susceptibility region for SLE in Finnish 
families, we genotyped more markers along 10 cM streches on either side of the best NPL-
scores on chromosomes 6q and 14q. On chromosome 6q, there were 25 markers across a 22 
cM region, from D6S308 to D6S1035. On chromosome 14q, there were 32 additional 
markers, covering a region of 24 cM between markers D14S70 and D14S63. In spite of a few 
gaps of 2 to 4 cM within these regions, the average marker interval remained 1 cM or less. 
The NPL-scores after finemapping are shown in Figure 6. 
 
Including data from 32 additional markers, the information content for chromosome 14q 
increased from 50 to 60% in the genome-wide scan to 72%. The highest NPL-score of 2.22 (p 
= 0.015) was observed at marker D14S1055, which lies 5 cM centromeric to the previous 
linkage peak at D14S587. 
 
The haplotype association was studied and analyzed using TDT and HPM. Eighty-nine trios 
from 65 families were analyzed. Two distinct regions with excess allele sharing were 
identified. A significant association of a 2 cM long haplotype was seen in 10 chromosomes at 
53.2-55.2 cM (markers D14S978-D14S589-D14S562, alleles 3-2-8). The pattern was not seen 
in the control chromosomes (the odds ratio could not be computed; X2 = 9.95, p = 0.00598 for 
marker D14S562). The next region of allele sharing was a few cM centromeric to the previous 
one, at 50.1-50.2 between markers D14S1009-D14S748 (alleles 3-1). This haplotype was 
shared by 15 chromosomes of SLE patients, and was also present in 2 control chromosomes, 
but did not, however, reach significance (X2 = 9.99, empirical p = 0.14, odds ratio = 13, 95% 
CI 2.9-59). For these 2 shared haplotypes, only 5 meiosis were informative for TDT analyses. 
The 3-2-8 was transmitted 4 times, and not-transmitted once (p = 0.18). The 3-1 haplotype 
was transmitted 6 times, and not-transmitted twice (p = 0.157). The TDT remained thus 
inconclusive. 
 
There were three individuals who posessed both haplotypes 3-1 and 3-2-8 on the same 
chromosomes, suggesting a common origin. The longest shared haplotype between two 
unrelated SLE patients covered 8 cM, from D14S288-D14S281 (Fig. 7). 
 
Data from 25 mapped markers across a 22 cM region on chromosome 6q were analyzed. The 
information content was 74%. The highest observed NPL score was 2.27 (p = 0.013), slightly 
lower than that observed in the genome scan (NPL= 2.47). The peak marker D6S1708 (at 
157.8 cM) was 6 cM telomeric from the previous peak at D6S960 (at 151.4 cM). The NPL 
scores and the corresponding information content are shown in Figure 6.  
Trios used for the HPM and TDT analyses were the same as for 14q analysis. There was some 
allele sharing between markers D6SGATA184A08 and D6S1637 (alleles 1 and 3) at 147-148 
cM, 10 cM away from the linkage peak. Haplotype 1-3 was seen in 27 patient chromosomes 
and in 9 control chromosomes (X2 = 8.02, empirical p = 0.0719 for marker D6S1637, odds 
ra
transmitted 15 times, and not transmitted 5 times (X2 = 5.00, p = 0.025). 
 
Of the patients with excessive haplotype sharing, 5 out of the 10 chromosomes (5/9 fam
ith a 3-2-8-haplotype on chromocome 14q originaw
a
n
There were 3 families (2 originating from Savo) in which both haplotypes on chromosome 
4q and the haplotype on chromosome 6 were present, and 5 families (3 originating from 
 
 
            
 
 
 
 
1
Savo) had 6 patients, in which 2 haplotypes from both chromosome 14q and 6q were present. 
Excluding close relationships between the families, such haplotype sharing is highly 
unexpected if not associated with the selection criterion (i.e., SLE), and the clustering of the 
associated haplotypes in eastern Finland may suggest a founder effect, possibly involving two 
loci on chromosomes 14q and 6q. 
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Fig. 7. Detailed analysis of independent SLE-associated haplotypes for marker loci on 14q from a set of patients of 35 
multiplex and 31 singleton (Savo) Finnish families. The haplotype 3-2-8 is present in 10 patients and no controls and is 
transmitted 4 times and not transmitted once. The haplotype 3-1, present in 15 patients and 2 controls, is transmitted 6 times 
and not transmitted 2 times.
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Figure 6. A. Linkage maps of chromosomes 6 and 14 from 35 Finnish families multiply affected by SLE, full chromosome 
views (Koskenmies et al. 2003). The distances between markers in linkage regions (black bars) are on average 3.5 cM. 
B. Combined linkage results from 35 multiplex and 31 singleton (Savo) families after addition of fine-mapping markers, 
detailed maps. The intermarker distances are < 1cM. Gray bars show the shared associating haplotypes in 10 patients by 
HPM analysis. Detailed haplotypes are shown in Figure 7. 
C. Association analyses using HPM. The dotted line depicts the empirical significance level of 0.01. The y-axis  shows the p-
value, expressed in logarithmic scale. The x-axis shows the genotyped region in cM (same scale as panel B). 
DISCUSSION 
 
1. Clinical studies 
 
In order to evaluate whether familial SLE influences disease expression, as evidence for a 
stronger genetic background, we compared the clinical manifestations in patients with 
sporadic and familial SLE. Familial and sporadic forms of same diseases can be clinically 
distinguished. For example, human non-polyposis colorectal cancer is an autosomal 
dominantly inherited colorectal cancer, which differs from the sporadic form by an earlier age 
of onset (<50 years), a right-sided location in the colon, and a family history of colorectal 
and/or other extra-intestinal cancers (Aaltonen and Peltomäki 1994; Vasen 1994; Suh et al. 
2002). Also, familial adenomatous polyposis, another dominantly inherited colorectal cancer, 
affect individuals at a younger age, and is often associated with extra-intestinal manifestations 
including cutaneous cysts, osteomas, desmoids, and cancers (Giardiello et al. 1997). In both 
of these hereditary colorectal cancers several gene mutations have been already identified 
(Aaltonen et al. 1993; Aaltonen and Peltomaki 1994; Giardiello et al. 1997; Suh et al. 20029). 
Additionally, a familial form of Alzheimer´s disease, affecting approximately 10% of 
patients, has been identified. Patients having these mutations are young at age at onset, and 
have affected first-degree relatives (Haass and Baumeister 1998; St. George-Hyslop 2000).  
  
Studies comparing the clinical manifestations in patients with sporadic and familial SLE are 
few. In 1976, Arnett and Schulman compared the phenotypes of first-degree relatives with 
SLE with those of patients with sporadic and familial SLE. They found a clear concordance 
for disease expression between affected first-degree relatives (parent/offspring and 
monozygotic twins) within families, but also found that different families were concordant for 
different phenotypes. These findings support both the genetic influence in development of the 
disease and the genetically heterogeneous nature of SLE. As there were no differences in 
clinical manifestations of patinents with sporadic and familial SLE, Arnett and Shulman 
concluded that familial SLE is unlikely to be a different disease entity from non-familial SLE. 
 
In the present study, we compared clinical manifestations and laboratory findings of 113 
patients from 53 multiplex families with those of 113 sporadic cases, mached by age, sex and 
duration of disease. We did not look at the concordance of disease expression between family 
members in multiplex families. Our multiplex families included second degree relatives, and 
even more distantly related pedigree members, because the patient collection was originally 
focused on genetic studies, and hence all available affected pedigree members were collected, 
and also clinically characterized. We found no differencies in clinical manifestations between 
sporadic and familial SLE patients. Our results coincide with those found in previous studies 
(Arnett and Schulman 1976; Gourley et al. 1996; Michel et al. 2001). 
 
Although the clinical expression of SLE varies widely, the four most prevalent clinical 
manifestations in our patients were the presence of ANA, arthritis, photosensitivity, and 
malar/butterfly rash. This is in accordance with other clinical studies of SLE (Gudmundsson 
and Steinsson 1990; Gourley et al. 1996; Michel et al. 2001) regardless of ethnicity. The 
t 
 and 15%, 
frequency of nephritis in our patients was lower (27-29%) than previously reported (Arnet
and Shulman 1976; Tan et al. 1982; Cervera et al. 1993). Whether this is due to ethnic 
diversity or methodological differences is unclear. In a nationwide Icelandic study 
(Gudmundson and Steinsson 1990), and in an Irish study of familial SLE (Gourley et 
al.1996), the frequencies of renal manifestations were close to our findings (20%
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respectively). To study susceptibility genes in SLE, one should concentrate on those patients 
evere symptoms. This, however, requires a large number of families, and 
 a small country such as Finland, this may be difficult to accomplish for a rare disease like 
sfull linkage studies on stratifying patients based on neurological 
anifestations, as an example, have been obtained worldwide (Nath et al. 2002). 
f 
tients with SLE or APS have a higher prevalence of anticardiolipin antibodies (aCL), 
efinitive conclusions of the existence of familial ASP can be drawn from our study. 
ese antibodies, 
uggesting that the etiopathogenesis of thrombosis in patients with familial SLE is 
linkage, was included in our primary genome-wide scan. In spite of the suggested 
with rare or more s
in
SLE. Some succes
m
 
In a study by Michel et al. (2001) autoimmune diseases other than SLE were evaluated in 
relatives of affected SLE patients. More than 20% of first-degree relatives of a patient, and as 
many as 11% of lupus propands, were found to have another distinct SLE associated 
autoimmune disease. Similar results have been reported earlier (Arnett 1997). The frequency 
of other autoimmune diseases in sporadic patients or their relatives was not reported. It has 
been speculated (Michel et al. 2001) that because autoimmune diseases may share some 
common susceptibility genes, families with multiple cases of various autoimmune disorders 
should be considered in genetic studies. In our genome-wide scan study, there were only 2 
patients and 3 first-degree relatives, who were reported to have another autoimmune disease, 
other than SLE. However, with a total number of 169 genotyped individuals, these 5 cases 
could not have any influence on the linkage results. 
  
The main motivation for Study II was to investigate one SLE subphenotype, antiphospholipid 
syndrome (APS), as a possible tool for further genetic studies. First-degree relatives o
pa
suggesting a genetic predisposition to the development of these antibodies (Mackworth-
Young et al 1987; Goldberg et al. 1995). The strongest evidence for a familial form of APS 
has been the identification of several kindreds with an increased frequency of 
antiphospholipid antibodies and the associated clinical manifestations, including thrombosis 
and recurrent abortions (Mackie et al. 1987; Matthey et al. 1989; Ford et al. 1990). In our 
study, there was no difference between multiplex and sporadic families in the occurrence of 
thrombosis. Additionally, antiphospholipid antibodies were not more frequent in the relatives 
of patients in the 3 multiplex families, where thrombosis had occurred at least in two pedigree 
members with SLE. However, the number of families identified was very small, and hence no 
d
Moreover, the recruitment of patients was basically targeted toward genetic studies. This 
means that only those individuals important for linkage were recruited, and especially in a 
large kindred, the status of aPLs of many pedigree members were not evaluated, suggesting 
that a putative clustering of aPLs in our families may have been underestimated. Finally, aPLs 
are a heterogeneous group of antibodies associated with many clinical manifestations (such as 
infections and malignancies). This means that diseases other than APS in SLE patients and 
their relatives have to be taken into account when seeking possible clustering of 
antiphospholipid antibodies in a family. In our study, the thrombotic events, at least in some 
cases, were probably due to factors other than those associated with th
s
multifactorial.   
 
 
2. Genetic studies 
 
This is the first nationwide study mapping SLE susceptibility genes in the Finnish population. 
More than 80% of hospital patients with SLE in Finland population were recruited. From the 
identified families, 53 were multiply affected by SLE and 35 of these families, informative for 
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homogeneous population structure in Finland, we could not find any single major locus 
contributing to the disease in our sample set. Three loci, however, exceeded the linkage 
threshold of 1.7, corresponding to the definition of suggestive linkage genome-wide (Lander 
and Kruglyak 1995). With addition of markers after the primary scan, we were able to 
increase the information content genome wide, but could not reach the threshold for 
significant linkage for any locus. Ideally, one would like to verify the results in an 
dependent data set, but this is not possible because we had already sampled almost all 
DR3 (Harley et al. 1998; Tan and Arnett 
98). More recently, Gaffney et al. (1998) observed strong linkage to the HLA-region in 
kage results and to proceed toward genetic association study we performed 
ne mapping with a dense set map of markers in two identified regions on chromosomes 
4q22-q23 and 6q25-q27. These regions were chosen mainly because our genome wide scan 
th those of previous studies of SLE (14q) and other autoimmune diseases 
q). Even though linkage to the HLA region has been observed in previous studies, we did 
in
available SLE patients in Finland. These results can, however, be used to guide further 
association mapping with very high-density marker maps (Elston et al. 1996). 
  
Suggestive linkage was found in two previously reported regions on chromosomes 6p (near 
HLA region) and 14q21-q23 (Gaffney et al. 1998), and in two new locations. Linkage to 
chromosome 5p has not been described previously. Linkage on chromosome 6q25-q27 has 
some overlapping results with one previous SLE study (Moser et al. 1998), however, for a 
different map position. Linkage to the HLA region is in accordance with previous studies. The 
association between SLE and the HLA complex was reported already in 1970´s (Grumet et al. 
1971), and since then, studies in patients of European descent have consistently shown an 
associations, especially between SLE and DR2 and 
19
their genome- wide scan, with supporting results from studies by Shai et al. (1999) and 
Lindqvist et al. (2000).  
 
Linkage to 14q21-q23 has been suggested in three previous genome wide scans. The best 
NPL score (2.81, p < 0.0016) was at marker D14S276 (Gaffney et al. 1998), which lies only 1 
cM telomeric from the linkage peak in our genome wide scan. High LODs were also found 
for D14S258 (LOD = 2.02, p = 0.02) (Shai et al. 1999), and D14S592 (LOD = 1.5) (Lindqvist 
et al. 2000). These data indicates locus heterogeneity between the different datasets, and even 
though none of these studies yielded significant linkage, they support evidence for SLE 
susceptibility on chromosome 14q.  
 
The relevance of linkages to 5p and 6q were more difficult to evaluate. Linkage to 
chromosome 5p has not been demonstrated previously, while linkage to 6q, about 20 cM 
telomeric to our linkage peak, has been implicated in one previous SLE study (Moser et al. 
1998). In studies with other autoimmune diseases, however, linkages to the same general 
region have been identified. A significant lod score of 4.5 (between markers D6S476 and 
D6S473) was observed on 6q (IDDM5) for type I diabetes (Davies et al. 1996; Todd 1997). In 
patients with rheumatoid arthritis there is evidence for linkage disequilibrium on chromosome 
6q, at markers D6S446, D6S311 and D6S440 (Myerscough et al. 2000). Our linkage peak at 
D6S960 (NPL = 2.47, p = 0.08) is 2 cM away from theirs peak at D6S440. Linkage to 
chromosome 6q in different autoimmune diseases suggests that chromosome 6q25-27 may 
harbour a gene influencing predisposition to autoimmunity. 
 
To verify our lin
fi
1
results coincided wi
(6
not include it in our fine-mapping, as the HLA region (because of it´s importance in many 
autoimmune disese) has been and is being studied worldwide. While planning the fine 
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mapping project, the sequence of chromosome 5 in public sequence repositories was still very 
fragmented, and hence fine mapping of this region was postponed. 
 
The fine-mapping was performed using microsatellite markers with an average marker 
distance of 1 cM. Families originating from a restricted Savo region in central eastern Finland 
were added to our data set under the hypothesis of shared ancestral mutations among the 
patients. This geographical region has shown founder effects for hereditary nonpolyposis 
colorectal cancer and chloride diarrhea, which both are monogenic diseases (Nystrom-Lahti et 
al. 1994; Hoglund et al. 1995). 
 
There was excess allele sharing in both chromosomes, 6q and 14q, and clustering of 
scan, verifying the linkage region. Moreover, the over-
ansmitted haplotype coincides with the peak for rheumatoid arthritis (Myerscough et al. 
associated haplotypes in Savo samples. The length of the associated haplotype was 2 cM on 
chromosome 14q (alleles 3-2-8) and 1 cM on chromosome 6q (alleles 1-3). The length of the 
associated haplotypes is roughly in accordance with the population history. The area was 
settled in the early 16th century, and founder effects have been noted there (Lahermo et al. 
1996; de la Chapelle 1998). Despite the small number of associated families, we found 
significantly excessive haplotype sharing between patients (IV). Two patients sharing a long 
conserved haplotype (8cM) originated from neighbouring Savo parishes, but the patients´ 
relationship was excluded at least back to the mid-19th century. Moreover, six patients from 
five unrelated families shared conserved haplotypes for two loci on different chromosomes, 
6q and 14q, an observation which is highly unlikely if not causally associated with the 
disease. 
 
The results from our association study verified the linkage regions identified in our genome- 
wide scan, and refined the search regions considerably. The conserved haplotype on 
chromosome 14q is located next to the best linkage peak observed in our genome wide scan, 
and coincides with the peak of Gaffney et al. (1998). 
  
For chromosome 6q, the conserved haplotype lies 3 cM centromeric from the observed 
linkage peak in our genome wide 
tr
2000), suggesting that this general region is highly interesting not only for SLE susceptibility 
genes, but also for possible genes influencing the predisposition to autoimmunity in general. 
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CONCLUSIONS AND FUTURE PROSPECTS 
 
This study was performed to search for susceptibility genes among Finnish families multiply 
subphenotype, antiphospholipid syndrome, did not reveal any 
vidence for familial aggregation of antiphospholipid antibodies in association with 
he association study was performed on 2 of the linkage regions, on chromosomes 6q and 
ed with those of three independent data 
ts, and refined the search regions considerably. Our results are compatible with the idea of a 
e 
entified haplotypes on both chromosomes 14q and 6q, further fine-mapping with tightly- 
spaced SNP markers within and near the haplotypes will be conducted. Thereafter, positional 
cloning can proceed to verify new transcripts and to study their polymorphisms and possible 
associations with SLE in this and other sample sets. Our research group envisions that these 
genetic studies, incorporating careful clinical evaluation of patients, systematic linkage and 
association studies, and finally, future positional identification of susceptibility genes, will 
contribute to our understanding of mechanisms in this puzzling disease.  
 
 
 
affected by SLE. A total of 53 multiplex families were identified during an intensive 
recruitment phase covering more than 80% of all hospital-based SLE patients in Finland. The 
clinical characteristics of SLE patients in multiplex families were evaluated, and were 
compared with those of families with sporadic patients, but no obvious phenotype for 
“familial” SLE, as a tool for further genetic analyses, was found. Moreover, stratifying our 
patients according to one SLE 
e
thrombosis in multiplex families. Hence, clinically, familial and sporadic SLE were shown to 
be the same entity, suggesting that results from further genetic studies in multiplex families 
can be extrapolated to all patients with SLE. 
 
We found no single major gene contributing to the risk of the disease in Finland, despite its 
population structure. However, in 35 families multiply affected by SLE, we found a 
suggestive linkage to four loci, providing further evidence for SLE loci at two of these, on 
chromosome 6p and 14q. Linkage to chromosome 5p has not been described previously, 
whereas linkage to chromosome 6q was reported in one previous SLE study. The same 
genomic region on 6q has also been identified in studies with type I diabetes and rheumatoid 
arthritis, and hence can harbour a gene influencing the predisposition for autoimmunity.  
 
T
14q. With 31 additional families originating from central eastern Finland, a region with a 
known founder effect, we observed excess sharing of a haplotype on 14q and excess 
transmission of a haplotype on 6q. Our finding not only verified the suggestive linkage results 
observed in our genome-wide scan, but also coincid
se
founder effect for susceptibility genes in SLE in central eastern Finland, and suggest a path to 
the isolation of putative susceptibility genes. 
 
In the near future, our aim is to fine map the linkage region on chromosome 5p in order to 
verify these linkage results. Moreover, to confirm the suggested identity-by-descent of th
id
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e marker order for fine-mapping) th
 
UCSC Genome Bioinformatics Site http://genome.ucsc.edu (for verifying the marker order in 
fine-mapping) 
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